UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


☒			Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended March 31, ~~2021~~2022


☐			Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from _______ to _______

Commission File Number 001-38694

LIVENT CORPORATION

(Exact name of registrant as specified in its charter)

__________________________________________________________________________


Delaware			82-4699376
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

~~2929 Walnut~~1818 Market Street	Philadelphia	Pennsylvania	~~19104~~19103
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: 215-299-5900

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	LTHM	New York Stock Exchange

INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL REPORTS REQUIRED TO BE FILED BY SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE REGISTRANT WAS REQUIRED TO FILE SUCH REPORTS), AND (2) HAS BEEN SUBJECT TO SUCH FILING REQUIREMENTS FOR THE PAST 90 DAYS. YES ☒ NO ☐

INDICATE BY CHECK MARK WHETHER THE REGISTRANT HAS SUBMITTED ELECTRONICALLY EVERY INTERACTIVE DATA FILE REQUIRED TO BE SUBMITTED PURSUANT TO RULE 405 OF REGULATION S-T (§232.405 OF THIS CHAPTER) DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE REGISTRANT WAS REQUIRED TO SUBMIT SUCH FILES). YES ☒ NO ☐

INDICATE BY CHECK MARK WHETHER THE REGISTRANT IS A LARGE ACCELERATED FILER, AN ACCELERATED FILER, A NON-ACCELERATED FILER, A SMALLER REPORTING COMPANY, OR AN EMERGING GROWTH COMPANY. SEE THE DEFINITIONS OF “LARGE ACCELERATED FILER,” “ACCELERATED FILER,” “SMALLER REPORTING COMPANY,” AND "EMERGING GROWTH COMPANY" IN RULE 12B-2 OF THE EXCHANGE ACT.

LARGE ACCELERATED FILER

☒

ACCELERATED FILER

☐

NON-ACCELERATED FILER

☐

SMALLER REPORTING COMPANY

☐

EMERGING GROWTH COMPANY

☐

IF AN EMERGING GROWTH COMPANY, INDICATE BY CHECK MARK IF THE REGISTRANT HAS ELECTED NOT TO USE THE EXTENDED TRANSITION PERIOD FOR COMPLYING WITH ANY NEW OR REVISED FINANCIAL ACCOUNTING STANDARDS PROVIDED PURSUANT TO SECTION 13(A) OF THE EXCHANGE ACT.

☐

INDICATE BY CHECK MARK WHETHER THE REGISTRANT IS A SHELL COMPANY (AS DEFINED IN RULE 12B-2 OF THE EXCHANGE ACT). YES ☐ NO ☒

As of March 31, ~~2021,~~2022, there were ~~146,565,688~~161,745,365 shares of Common Stock, $0.001 par value per share, outstanding.

LIVENT CORPORATION

INDEX


			Page No.
Glossary of Terms			3
Part I - FINANCIAL INFORMATION			4
Item 1. Financial Statements			4
Condensed Consolidated Statements of Operations - Three Months Ended March 3 1 , 202 12 and 20202 201 (unaudited)			4
Condensed Consolidated Statements of Comprehensive Income/(Loss)~~/Income~~ - Three M ~~onths~~Months Ended March 31, ~~2021~~2022 and 20 20 2021 (unaudited)			5
Condensed Consolidated Balance Sheets - March 31, ~~2021~~ ~~(unaudited)~~2021(unaudited) and December 31,~~, 202~~0 2021			6
Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, ~~2021~~2022 and 20 20 2021 (unaudited)			7
Condensed Consolidated Statements of Equity - Three Months Ended March 31, ~~2021~~2022 and 20 20 2021 (unaudited)			89
Notes to Condensed Consolidated Financial Statements (unaudited)			910
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			2824
Item 3. Quantitative and Qualitative Disclosures About Market Risk			3835
Item 4. Controls and Procedures			3835
Part II - OTHER INFORMATION			3936
Item 1. Legal Proceedings			3936
Item 1A. Risk Factors			3936
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds			3936

Item 6. Exhibits			4037
Signatures			4138

Glossary of Terms

When the following terms and abbreviations appear in the text of this report, they have the meanings indicated below:


2025 Notes			$245.75 million principal amount 4.125% Convertible Senior Notes due 2025 ~~including $20.75 million issued upon exercise of the Over-Allotment Option on July 7, 2020.~~
~~Application~~			~~The application filed by Livent with the CCAA Court to obtain remittance of the Escrow Funds~~
~~ASC~~			~~Accounting Standards Codification, under U.S. GAAP~~
~~ASC 842~~			~~Accounting Standards Codification Topic 842 - Leases~~
ASU			Accounting Standards Update, under U.S. GAAP
~~ASU 2020-06~~			ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity
~~CCAA~~			~~The Companies’ Creditors Arrangement Act (Canada)~~
~~CCAA Court~~			~~The Superior Court of Québec where Nemaska, Nemaska Lithium Inc. and certain affiliates filed for creditor protection in Canada under the CCAA~~
Credit Agreement			The Original Credit Agreement, as amended ~~on May 6, 2020, by the First Amendment and August 3, 2020, by the Second Amendment~~
EAETR			Estimated annual effective tax rate
~~Escrow Funds~~			~~The funds held in escrow by a third party for the benefit of Livent in connection with the Nemaska matter~~
ESG			Environmental, social and governance
EV			Electric vehicle
FASB			Financial Accounting Standards Board
~~First Amendment~~			~~On May 6, 2020, Livent Corporation entered into the First Amendment to the Credit Agreement to amend and restate the Original Credit Agreement~~
FMC			FMC Corporation
~~FMC Plan~~			~~FMC Corporation Incentive Compensation and Stock Plan~~
~~IPO~~			~~Initial public offering~~
Livent NQSP			Livent Non-Qualified Savings Plan
~~Livent Plan~~			~~Livent Corporation Incentive Compensation and Stock Plan~~
Nemaska			Nemaska Lithium Shawinigan Transformation Inc., a subsidiary of Nemaska Lithium Inc., a Canadian lithium company based in Québec, Canada
Nemaska Project			The ownership and operation of the business previously conducted by Nemaska, by a consortium in which Livent indirectly owns a 25% equity interest through its investment in QLP.
Nemaska Transaction			The transaction through which a consortium has purchased and ~~will operate~~operates the business previously conducted by Nemaska Lithium Inc.~~, a Canadian lithium producer~~


Offering			On June 15, 2021, the Company closed on the issuance of 14,950,000 shares of its common stock, par value $0.001 per share, at a public offering price of $17.50 per share, in an underwritten public offering. Total net proceeds from the offering were $252.2 million.
OEM			Original equipment manufacturer
Original Credit Agreement			On September 18, 2018 Livent Corporation entered into the credit agreement, which provides for a $400 million senior secured revolving credit facility
~~Over-Allotment Option~~PRSU			~~Option to purchase an additional $20.75 million principal amount of 2025 Notes exercised on July 7, 2020.~~Performance-based restricted stock unit
QLP			Québec Lithium Partners, a joint venture owned equally by The Pallinghurst Group and Livent. QLP owns a 50% equity interest in the Nemaska Project.
Revolving Credit Facility			Livent's $400 million senior secured revolving credit facility
RSU			Restricted stock unit
SEC			Securities and Exchange Commission
~~Second Amendment~~			~~On August 3, 2020, Livent Corporation entered into the Second Amendment to the Credit Agreement to amend the Credit Agreement~~
Securities Act			Securities Act of 1933
Separation			On October 15, 2018, Livent completed its ~~IPO~~initial public offering and sold 20 million shares of Livent common stock to the public at a price of $17.00 per share

~~Tax Act~~TSR			~~Tax Cuts and Jobs Act~~Total Shareholder Return
U.S. GAAP			United States Generally Accepted Accounting Principles
VAT			Value-added tax

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

LIVENT CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended March 31,
2021 2020
(in Millions, Except Per Share Data) (unaudited)
Revenue $ 91.7 $ 68.5
Cost of sales 78.4 53.9
Gross margin 13.3 14.6
Selling, general and administrative expenses 10.7 10.8
Research and development expenses 0.7 1.0
Restructuring and other charges 0.3 4.8
Separation-related costs (0.1) 0.1
Total costs and expenses 90.0 70.6
Income/(loss) from operations before equity in net loss of unconsolidated affiliates, interest expense, net and income taxes 1.7 (2.1)
Equity in net loss of unconsolidated affiliates 1.3 0.1
Interest expense, net 0.3 0
Income/(loss) from operations before income taxes 0.1 (2.2)
Income tax expense/(benefit) 0.9 (0.3)
Net loss $ (0.8) $ (1.9)
Net loss per weighted average share - basic and diluted $ (0.01) $ (0.01)
Weighted average common shares outstanding - basic and diluted 146.5 146.1


	Three Months Ended March 31,
	2022		2021
(in Millions, Except Per Share Data)	(unaudited)
Revenue	$	143.5	$	91.7
Cost of sales	83.6		78.4
Gross margin	59.9		13.3
Selling, general and administrative expenses	11.8		10.7
Research and development expenses	0.9		0.7
Restructuring and other charges	1.0		0.3
Separation-related costs/(income)	0.1		(0.1)
Total costs and expenses	97.4		90.0
Income from operations before equity in net loss of unconsolidated affiliate, interest expense, net and other gain	46.1		1.7
Equity in net loss of unconsolidated affiliate	2.2		1.3

Interest expense, net	—		0.3
Other gain	(14.0)		—
Income from operations before income taxes	57.9		0.1
Income tax expense	4.7		0.9


Net income/(loss)	$	53.2	$	(0.8)
Net income/(loss) per weighted average share - basic	$	0.33	$	(0.01)
Net income/(loss) per weighted average share - diluted	$	0.28	$	(0.01)
Weighted average common shares outstanding - basic	161.7		146.5
Weighted average common shares outstanding - diluted	191.4		146.5

The accompanying notes are an integral part of these condensed consolidated financial statements.

LIVENT CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE ~~LOSS~~INCOME/(LOSS)

Three Months Ended March 31,
2021 2020
(in Millions) (unaudited)
Net loss $ (0.8) $ (1.9)
Other comprehensive loss, net of tax:
Foreign currency adjustments:
Foreign currency translation loss arising during the period (0.3) (1.8)
Total foreign currency translation adjustments (1)
(0.3) (1.8)
Other comprehensive loss, net of tax (0.3) (1.8)
Comprehensive loss $ (1.1) $ (3.7)

~~____________________~~

1.Income taxes are not provided on the equity in undistributed earnings of our foreign subsidiaries because it is our intention that such earnings will remain invested in those subsidiaries indefinitely.


	Three Months Ended March 31,
	2022		2021
(in Millions)	(unaudited)
Net income/(loss)	$	53.2	$	(0.8)
Other comprehensive loss, net of tax:
Foreign currency adjustments:
Foreign currency translation loss arising during the period	(1.0)		(0.3)

Total foreign currency translation adjustments	(1.0)		(0.3)
Derivative instruments:
Unrealized hedging gains, net of tax of $0.1	0.1		—

Total derivative instruments, net of tax of $0.1	0.1		—
Other comprehensive loss, net of tax	(0.9)		(0.3)
Comprehensive income/(loss)	$	52.3	$	(1.1)

The accompanying notes are an integral part of these condensed consolidated financial statements.

LIVENT CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(in Millions, Except Share and Par Value Data) March 31, 2021 December 31, 2020
ASSETS (unaudited)
Current assets
Cash and cash equivalents $ 21.5 $ 11.6
Trade receivables, net of allowance of $0.4 in 2021 and $0.4 in 2020 82.7 76.3
Inventories, net 96.7 105.6
Prepaid and other current assets 40.6 56.3
Total current assets 241.5 249.8
Investments 22.8 23.8
Property, plant and equipment, net of accumulated depreciation of $228.1 in 2021 and $222.4 in 2020 560.0 545.3
Deferred income taxes 12.1 13.4
Right of use assets - operating leases, net 4.9 16.1
Other assets 87.3 88.4
Total assets $ 928.6 $ 936.8
LIABILITIES AND EQUITY
Current liabilities
Accounts payable, trade and other $ 38.7 $ 43.9
Accrued customer rebates 0 0.3
Accrued and other current liabilities 20.4 36.7
Operating lease liabilities - current 0.7 1.4
Income taxes 0.4 0
Total current liabilities 60.2 82.3
Long-term debt 298.9 274.6
Operating lease liabilities - long-term 4.3 14.8
Environmental liabilities 6.2 6.1
Deferred income taxes 6.1 5.6
Other long-term liabilities 17.3 17.2
Commitments and contingent liabilities (Note 13) 0 0
Total current and long-term liabilities 393.0 400.6
Equity
Common stock; $0.001 par value; 2 billion shares authorized in 2018; 146,665,594 and 146,461,249 shares issued; 146,565,688 and 146,361,981 outstanding at March 31, 2021 and December 31, 2020, respectively
0.1 0.1
Capital in excess of par value of common stock 521.5 520.9
Retained earnings 59.5 60.3
Accumulated other comprehensive loss (44.7) (44.4)
Treasury stock, common; 99,906 and 99,268 shares at March 31, 2021 and December 31, 2020, respectively
(0.8) (0.7)
Total equity 535.6 536.2
Total liabilities and equity $ 928.6 $ 936.8


(in Millions, Except Share and Par Value Data)	March 31, 2022		December 31, 2021
ASSETS	(unaudited)
Current assets
Cash and cash equivalents	$	68.5	$	113.0
Trade receivables, net of allowance of approximately $0.3 in 2022 and $0.3 in 2021	105.5		96.4
Inventories, net	150.5		134.6
Prepaid and other current assets	40.0		55.3


Total current assets	364.5		399.3
Investments	33.4		27.2
Property, plant and equipment, net of accumulated depreciation of $246.2 in 2022 and $243.0 in 2021	737.8		677.9



Deferred income taxes	—		0.9
Right of use assets - operating leases, net	6.0		6.3
Other assets	100.9		90.9
Total assets	$	1,242.6	$	1,202.5
LIABILITIES AND EQUITY
Current liabilities

Accounts payable, trade and other	$	62.2	$	65.4


Accrued and other liabilities	54.2		61.8
Operating lease liabilities - current	1.1		1.1



Income taxes	2.8		3.0

Total current liabilities	120.3		131.3
Long-term debt	240.8		240.4
Operating lease liabilities - long-term	5.0		5.4
Environmental liabilities	5.7		5.6
Deferred income taxes	7.7		12.7
Other long-term liabilities	14.1		11.7
Commitments and contingent liabilities (Note 13)	—		—
Total current and long-term liabilities	393.6		407.1
Equity
Common stock; $0.001 par value; 2 billion shares authorized; 161,848,607 and 161,791,602 shares issued; 161,745,365 and 161,689,984 outstanding as of March 31, 2022 and December 31, 2021, respectively	0.1		0.1
Capital in excess of par value of common stock	779.4		778.1
Retained earnings	114.1		60.9
Accumulated other comprehensive loss	(43.8)		(42.9)
Treasury stock, at cost; 103,242 and 101,618 shares as of March 31, 2022 and December 31, 2021, respectively	(0.8)		(0.8)


Total equity	849.0		795.4
Total liabilities and equity	$	1,242.6	$	1,202.5

The accompanying notes are an integral part of these condensed consolidated financial statements.

LIVENT CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


	Three Months Ended March 31,
	2022		2021
(in Millions)	(unaudited)
Cash provided by operating activities:
Net income/(loss)	$	53.2	$	(0.8)
Adjustments to reconcile net income/(loss) to cash provided by operating activities:
Depreciation and amortization	6.4		6.2
Restructuring and other charges	0.8		0.1
Deferred income taxes	0.8		1.3
Separation-related (income)/costs	(0.3)		0.6
Share-based compensation	1.6		1.1
Change in investments in trust fund securities	0.2		(0.2)
Loss on disposal of assets	0.1		—
Deferred financing fees amortization	—		0.3
Equity in net loss of unconsolidated affiliate	2.2		1.3
Other gain, Blue Chip Swap	(14.0)		—
Changes in operating assets and liabilities:
Trade receivables, net	(9.3)		(6.3)
Inventories	(16.5)		9.1
Accounts payable, trade and other	(3.2)		(5.2)

Changes in deferred compensation	0.7		0.6
Income taxes	(0.1)		0.4
Change in prepaid and other current assets and other assets	5.1		16.5
Change in accrued and other current and long-term liabilities	(16.9)		(12.3)
Cash provided by operating activities	10.8		12.7
Cash used in investing activities:
Capital expenditures(1)	(68.7)		(25.5)
Investments in Livent NQSP securities	(0.7)		(0.6)
Proceeds from Blue Chip Swap, net of purchases	14.0		—
Other investing activities	—		(0.9)
Cash used in investing activities	(55.4)		(27.0)
Cash provided by financing activities:
Proceeds from Revolving Credit Facility	—		37.0
Repayments of Revolving Credit Facility	—		(13.0)




Proceeds from issuance of common stock - incentive plans	0.1		0.2

Cash provided by financing activities	0.1		24.2

(Decrease)/increase in cash and cash equivalents	(44.5)		9.9
Cash and cash equivalents, beginning of period	113.0		11.6
Cash and cash equivalents, end of period	$	68.5	$	21.5

Three Months Ended March 31,
2021 2020
(in Millions)
(unaudited)
Cash provided/(required) by operating activities:
Net loss $ (0.8) $ (1.9)
Adjustments to reconcile net loss to cash provided/(required) by operating activities:
Depreciation and amortization 6.2 5.6
Restructuring and other charges 0.1 2.4
Deferred income taxes 1.3 0
Separation-related costs 0.6 (0.1)
Share-based compensation 1.1 1.0
Change in investments in trust fund securities (0.2) (0.3)
Deferred financing fees amortization 0.3 0
Equity in net loss of unconsolidated affiliates 1.3 0.1
Changes in operating assets and liabilities:
Trade receivables, net (6.3) 33.0
Inventories 9.1 (8.9)
Accounts payable, trade and other (5.2) (40.2)
Change in deferred compensation 0.6 0.4
Income taxes 0.4 (0.8)
Change in prepaid and other current assets and other assets 16.5 (2.7)
Change in accrued and other current liabilities and other long-term liabilities (12.3) 7.0
Cash provided/(required) by operating activities 12.7 (5.4)
Cash required by investing activities:
Capital expenditures(1)
(25.5) (56.0)
Investments in trust fund securities (0.6) (0.3)
Other investing activities (0.9) 0
Cash required by investing activities (27.0) (56.3)
Cash provided by financing activities:
Proceeds from Revolving Credit Facility 37.0 95.5
Repayments of Revolving Credit Facility (13.0) (39.0)
Proceeds from issuance of common stock 0.2 0
Cash provided by financing activities 24.2 56.5
Effect of exchange rate changes on cash and cash equivalents 0 (0.2)
Increase/(decrease) in cash and cash equivalents 9.9 (5.4)
Cash and cash equivalents, beginning of period 11.6 16.8
Cash and cash equivalents, end of period $ 21.5 $ 11.4
Supplemental Disclosure for Cash Flow:
Cash refunds for income taxes, net (2)
$ (1.2) $ (0.3)
Cash payments for interest, net (1)
$ 6.4 $ 2.2
Cash payments for Restructuring and other charges $ 0.2 $ 2.4
Cash payments for Separation-related charges $ (0.7) $ 0.2
Accrued capital expenditures $ 4.4 $ 23.5
Operating lease right-of-use assets and lease liabilities recorded for ASC 842 $ 0 $ 0.8

LIVENT CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)


	Three Months Ended March 31,
	2022		2021
Supplemental Disclosure for Cash Flow:	(unaudited)
Cash payments/(refunds) for income taxes, net of refunds	$	2.4	$	(1.2)
Cash payments for interest (1)	$	5.5	$	6.4
Cash payments for Restructuring and other charges	$	0.2	$	0.2
Cash payments/(receipts) for Separation-related charges	$	0.4	$	(0.7)
Accrued capital expenditures	$	29.0	$	4.4
Accrued investment in unconsolidated affiliate	$	8.0	$	—

____________________

1.For the three months ended March 31, 2022, and 2021, $4.0 million and $3.7 million of interest expense was ~~capitalized. All of the interest related to our Revolving Credit Facility was~~ capitalized, ~~for the three months ended March 31, 2020.~~

2.~~Three months ended March 31, 2020 includes $1.9 million refund from FMC related to the Company's 2018 federal income tax return.~~respectively.

The accompanying notes are an integral part of these condensed consolidated financial statements.

LIVENT CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)


(in Millions Except Per Share Data)	(in Millions Except Per Share Data)	Common Stock, $0.001 Per Share Par Value		Capital In Excess of Par		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock		Total		(in Millions Except Per Share Data)	Common Stock, $0.001 Per Share Par Value		Capital In Excess of Par		Retained Earnings		Accumulated Other Comprehensive Loss		Treasury Stock		Total

Balance, December 31, 2019		$	0.1	$	516.4	$	76.6	$	(48.3)	$	(0.8)	$	544.0
Net loss		—		—		(1.9)		—		—		(1.9)
Stock compensation plans		—		1.2		—		—		—		1.2
Shares withheld for taxes - common stock issuances		—		(0.7)		—		—		—		(0.7)
Foreign currency translation adjustments		—		—		—		(1.8)		—		(1.8)
Balance, March 31, 2020		$	0.1	$	516.9	$	74.7	$	(50.1)	$	(0.8)	$	540.8

Balance, December 31, 2020	Balance, December 31, 2020	$	0.1	$	520.9	$	60.3	$	(44.4)	$	(0.7)	$	536.2	Balance, December 31, 2020	$	0.1	$	520.9	$	60.3	$	(44.4)	$	(0.7)	$	536.2
Net loss	Net loss	—		—		(0.8)		—		—		(0.8)		Net loss	—		—		(0.8)		—		—		(0.8)
Stock compensation plans	Stock compensation plans	—		1.2		—		—		—		1.2		Stock compensation plans	—		1.2		—		—		—		1.2
Exercise of stock options	Exercise of stock options	—		0.2		—		—		—		0.2		Exercise of stock options	—		0.2		—		—		—		0.2

Shares withheld for taxes - common stock issuances	Shares withheld for taxes - common stock issuances	—		(0.8)		—		—		—		(0.8)		Shares withheld for taxes - common stock issuances	—		(0.8)		—		—		—		(0.8)
Net purchases of Treasury Stock - Non qualified Plan		—		—		—		—		(0.1)		(0.1)
Net purchases of treasury stock - Livent NQSP														Net purchases of treasury stock - Livent NQSP	—		—		—		—		(0.1)		(0.1)
Foreign currency translation adjustments	Foreign currency translation adjustments	—		—		—		(0.3)		—		(0.3)		Foreign currency translation adjustments	—		—		—		(0.3)		—		(0.3)
Balance, March 31, 2021	Balance, March 31, 2021	$	0.1	$	521.5	$	59.5	$	(44.7)	$	(0.8)	$	535.6	Balance, March 31, 2021	$	0.1	$	521.5	$	59.5	$	(44.7)	$	(0.8)	$	535.6

Balance, December 31, 2021														Balance, December 31, 2021	$	0.1	$	778.1	$	60.9	$	(42.9)	$	(0.8)	$	795.4
Net income														Net income	—		—		53.2		—		—		53.2
Stock compensation plans														Stock compensation plans	—		1.7		—		—		—		1.7
Exercise of stock options														Exercise of stock options	—		0.1		—		—		—		0.1
Shares withheld for taxes - common stock issuances														Shares withheld for taxes - common stock issuances	—		(0.5)		—		—		—		(0.5)
Net hedging gains, net of income tax														Net hedging gains, net of income tax	—		—		—		0.1		—		0.1
Foreign currency translation adjustments														Foreign currency translation adjustments	—		—		—		(1.0)		—		(1.0)
Balance, March 31, 2022														Balance, March 31, 2022	$	0.1	$	779.4	$	114.1	$	(43.8)	$	(0.8)	$	849.0

The accompanying notes are an integral part of these condensed consolidated financial statements.

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited)

Note 1: Description of the Business

Background and Nature of Operations

Livent Corporation (“Livent”, “we”, “us”, ~~"company"~~"Company" or “our”) manufactures ~~lithium for use in~~ a wide range of lithium products, which are used primarily in lithium-based batteries, specialty polymers and chemical synthesis applications. We serve a diverse group of markets. ~~Our product offerings are primarily inorganic and generally have few cost-effective substitutes.~~ A major growth driver for lithium in the future will be the ~~rate of~~increasing adoption of electric ~~vehicles.~~vehicles ("EVs") and other energy storage applications.

Most markets for lithium chemicals are global with significant growth occurring in Asia, followed by Europe and North America, primarily driven by the development and manufacture of lithium-ion batteries. We are one of the primary producers of performance lithium compounds.

~~Table of Contents~~

~~LIVENT CORPORATION~~

~~Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)~~

Note 2: Principal Accounting Policies and Related Financial Information

The accompanying condensed consolidated financial statements were prepared in accordance with the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by U.S. GAAP have been condensed or omitted from these interim financial statements. The financial statements included in this report reflect all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation of our condensed consolidated financial position atas of March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, the condensed consolidated results of operations for the three months ended March 31, ~~2021~~2022 and ~~2020,~~2021, and the condensed consolidated cash flows for the three months ended March 31, ~~2021~~2022 and ~~2020.~~2021. The unaudited results of operations for the interim periods reported are not necessarily indicative of results to be expected for the full year. These statements, therefore, should be read in conjunction with the annual consolidated ~~and combined~~ financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2020~~2021 (the ~~"2020~~"2021 Annual Report on Form 10-K").

~~Estimates and assumptions~~

~~In preparing~~Blue Chip Swap. Our wholly owned subsidiary in Argentina uses the ~~financial statements in conformity with~~ U.S. ~~GAAP, we are required to make estimates and assumptions that affect the reported amounts of~~dollar as their functional currency. Argentina peso-denominated monetary assets and liabilities are remeasured at each balance sheet date to the official currency exchange rate then in effect which represents the exchange rate available for external commerce (import payments and ~~disclosures~~export collections) and financial payments, with currency remeasurement and other transaction gains and losses recognized in earnings. In September 2019, the President of ~~contingent assets~~Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result, a legal trading mechanism known as the Blue Chip Swap emerged in Argentina for all individuals or entities to transfer U.S. dollars out of and ~~liabilities at~~into Argentina. The Blue Chip Swap rate is the ~~date~~implicit exchange rate resulting from the Blue Chip Swap transaction. Recently, the Blue Chip Swap rate has diverged significantly from Argentina’s official rate due to the economic environment. During the first quarter of 2022, to support our capital expansion projects, we transferred U.S. dollars into Argentina through the Blue Chip Swap method whereby our wholly owned Delaware subsidiary, MDA Lithium Holdings LLC, realized a cash gain, net of purchase costs, from the purchase in U.S. dollars and sale in Argentina pesos of Argentina Sovereign U.S. dollar-denominated bonds of U.S. $14.0 million, recorded to Other gain in our condensed consolidated statement of operations.

Performance-Based Restricted Stock Unit ("PRSU") Awards. The Company granted approximately sixty-three thousand PRSUs ("2022 PRSUs") to key employees on February 23, 2022, as authorized under the provisions of the ~~financial statements~~Livent Corporation 2018 Incentive Compensation and ~~the reported amounts~~Stock Plan.The number of ~~revenue and expenses during the reporting period.~~

~~Due~~PRSUs ultimately earned will be based on Livent's Total Shareholder Return ("TSR") relative to the ~~current coronavirus ("COVID-19") pandemic, there has been uncertainty and disruption~~TSR of the companies in the ~~global economy and financial markets.~~Russell 3000 Chemical Supersector Index over a three year performance period from January 1, 2022 through December 31, 2024 (the "Performance Period"). The ~~estimates used for, but not limited~~final number of PRSUs earned will range from 0% to 200% of the ~~collectability~~number of ~~trade receivables,~~PRSUs granted based on the Company's relative TSR performance over the Performance Period.

Because the value of the 2022 PRSUs is dependent upon the attainment of a level of TSR, it requires the impact of the market condition to be considered when estimating the fair value of ~~long-lived assets, income taxes, inventory~~the 2022 PRSUs. As a result, the Monte Carlo model is applied and the most significant valuation ~~and~~assumptions used related to the 2022 PRSUs during the year ending December 31, 2022, include:


Valuation date stock price			$21.01
Expected volatility			72.99%
Risk free rate			1.74%

The February 23, 2022 grant date fair value of ~~financial instruments could be impacted. We have assessed the impact and are not aware~~each PRSU granted was $20.82 per share.

Table of any specific events or circumstances that required an update to our estimates and assumptions or materially affected the carrying value of our assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

~~4.125% Convertible Senior Notes due 2025 (the “2025 Notes”)~~

~~We account for our 2025 Notes under Accounting Standards Update ("ASU") No. 2020-06,~~ Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity ~~("ASU 2020-06"), which we early adopted January 1, 2021 under the full retrospective method~~. ~~See Note 3 and Note 9 for details.~~Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)

There were no other significant changes to our accounting policies that are set forth in detail in Note 2 to our annual consolidated ~~and combined~~ financial statements in Part II, Item 8 of our ~~2020~~2021 Annual Report on Form 10-K.

Note 3: Recently Issued and Adopted Accounting Pronouncements and Regulatory Items

New accounting guidance and regulatory items

In ~~April 2020,~~ November 2021, the Financial Accounting Standard Board ("FASB") issued ASU No. 2021-10, Government Assistance (Topic 832). This ASU requires business entities to disclose information about government assistance they receive if the transactions were accounted for by analogy to either a grant or a contribution accounting model. The disclosure requirements include the nature of the transaction and the related accounting policy used, the line items on the balance sheets and statements of operations that are affected and the amounts applicable to each financial statement line item and the significant terms and conditions of the transactions. The ASU is effective for annual periods beginning after December 15, 2021. The disclosure requirements can be applied either retrospectively or prospectively to all transactions in the scope of the amendments that are reflected in the financial statements at the date of initial application and new transactions that are entered into after the date of initial application. We are evaluating the impact of this ASU on our consolidated financial statements.

In April 2020, FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). The amendments in this ASU provide optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. An entity may optionally elect to apply the amendments effective in the first interim period that includes or is subsequent to March 12, 2020 through December 31, 2022. We ~~are evaluating the effect the guidance will~~do not expect adoption to have ~~on our condensed consolidated financial statements.~~

~~Recently adopted accounting guidance~~

~~In August 2020, FASB issued ASU 2020-06.~~The ASU reduces the number of accounting models for convertible debt instruments by eliminating the cash conversion model. As compared with current U.S. GAAP, more convertible debt instruments will be reported as a single liability instrument and the interest rate of more convertible debt instruments will be closer to the coupon interest rate. The ASU also aligns the consistency of diluted Earnings Per Share ("EPS") calculations for convertible instruments by requiring that (1) an entity use the if-converted method and (2) share settlement be included in the diluted EPS calculation for both convertible instruments and equity contracts when those contracts include an option of cash settlement or share settlement. The ASU is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. We elected to early adopt ASU 2020-06 on January 1, 2021, using the full retrospective

~~Table of Contents~~

~~LIVENT CORPORATION~~

~~Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)~~

method. Prior to adoption, under Accounting Standards Codification 470-20, Debt with Conversion and Other Options ("ASC 470-20"), we had separately accounted for the liability and equity components of our 2025 Notes, which may be settled entirely or partially in cash upon conversion, in a manner that reflected the issuer’s economic interest cost. The effect of ASC 470-20 on the accounting for the 2025 Notes was that the equity component was required to be included in the additional paid-in capital section of stockholders’ equity on our consolidated balance sheet, and the value of the equity component was treated as original issue discount for purposes of accounting for the debt component of the 2025 Notes. As a result, prior to the adoption of ASU 2020-06, we were required to record a greater amount of non-cash interest expense as a result of the amortization of the discounted carrying value of the 2025 Notes to their face amount over the term of the 2025 Notes. Because we intend to settle in cash the principal outstanding under our 2025 Notes, we previously used the treasury stock method when calculating their potential dilutive effect, if any. ASU 2020-06 now requires us to use the if-converted method for EPS. For the full retrospective method of adoption, the accounting change was recognized as an adjustment to the balance of retained earnings, additional paid-in capital, long-term debt and deferred income taxes in our consolidated balance sheet as of December 31, 2020, the year in which the 2025 Notes were issued. See Note 9 and Note 11 for further details.

~~In December 2019, FASB issued ASU No. 2019-12,~~ ~~Simplifying the Accounting for Income Taxes(Topic 740).~~ The amendments in this ASU simplified the accounting for income taxes by removing certain exceptions to the general principle in Topic 740. The amendments also contain improvements and clarifications of certain guidance in Topic 740. The new amendments are effective for fiscal years beginning after December 15, 2020 (i.e. a January 1, 2021 effective date), with early adoption permitted. We adopted the amendments as of January 1, 2021 and the adoption did not have a material impact on our condensed consolidated financial statements.

Note 4: Revenue Recognition

Disaggregation of revenue

We disaggregate revenue from contracts with customers by geographical areas (based on product destination) and by product categories. The following table provides information about disaggregated revenue by major geographical region:


(in Millions)	(in Millions)	Three Months Ended March 31,			(in Millions)		Three Months Ended March 31,
			2021		2020				2022		2021
North America (1)	North America (1)		$	13.3	$	14.8		North America (1)	$	21.3	$	13.3
Latin America			0		0.1

Europe, Middle East & Africa	Europe, Middle East & Africa		17.5		11.3			Europe, Middle East & Africa	14.7		17.5
Asia Pacific (1)	Asia Pacific (1)		60.9		42.3			Asia Pacific (1)	107.5		60.9
Total Revenue	Total Revenue		$	91.7	$	68.5		Total Revenue	$	143.5	$	91.7

1.During the three months ended March 31, ~~2021,~~2022, countries with sales in excess of 10% of combined revenue consisted of Japan, the U.S., and China. Sales for the three months ended March 31, 2022 for Japan, the U.S., and China totaled $30.6 million, $20.8 million, $59.1 million, respectively. During the three months ended March 31, 2021, countries with sales in excess of 10% of combined revenue consisted of Japan, the U.S, China and South ~~Korea.~~Korea. Sales for the three months ended March 31, 2021 for Japan, the U.S., China and South Korea totaled $16.7 million, $13.1 million, $27.0 million and $11.1 million, ~~respectively. During~~respectively.

For the three months ended March 31, ~~2020, countries with~~ ~~sales~~2022, one customer accounted for approximately 26% of total revenue and our 10 largest customers accounted in ~~excess~~aggregate for approximately 69% of ~~10% of combined revenue consisted of Japan and the U.S. Sales for the three months ended March 31, 2020 for Japan and the U.S. totaled $31.1 million and $14.6 million, respectively.~~total revenue.

For the three months ended March 31, 2021, one customer accounted for approximately 37% of total revenue and our 10 largest customers accounted in aggregate for approximately 69% of ~~revenue.~~ ~~For the three months ended March 31, 2020, one customer accounted for approximately 39% of~~ total ~~revenue and our 10 largest customers accounted in aggregate for approximately 66% of our~~ revenue. A loss of any material customer could have a material adverse effect on our business, financial condition and results of operations.

The following table provides information about disaggregated revenue by major product category:

Table of Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)


(in Millions)	(in Millions)	Three Months Ended March 31,			(in Millions)		Three Months Ended March 31,
			2021		2020				2022		2021
Lithium Hydroxide	Lithium Hydroxide		$	49.8	$	37.7		Lithium Hydroxide	$	67.5	$	49.8
Butyllithium	Butyllithium		25.9		21.5			Butyllithium	33.7		25.9
High Purity Lithium Metal and Other Specialty Compounds	High Purity Lithium Metal and Other Specialty Compounds		8.9		8.0			High Purity Lithium Metal and Other Specialty Compounds	13.4		8.9
Lithium Carbonate and Lithium Chloride	Lithium Carbonate and Lithium Chloride		7.1		1.3			Lithium Carbonate and Lithium Chloride	28.9		7.1
Total Revenue	Total Revenue		$	91.7	$	68.5		Total Revenue	$	143.5	$	91.7

Contract asset and contract liability balances

The following table presents the opening and closing balances of our receivables, net of allowances. As ofof March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, there were 0no significant contract liabilities ~~from contract with customers.~~recorded in the consolidated balance sheets.


(in Millions)	(in Millions)	Balance as of March 31, 2021		Balance as of December 31, 2020		Increase (Decrease)		(in Millions)	Balance as of March 31, 2022		Balance as of December 31, 2021		Increase

Receivables from contracts with customers, net of allowances	Receivables from contracts with customers, net of allowances	$	82.7	$	76.3	$	6.4	Receivables from contracts with customers, net of allowances	$	105.5	$	96.4	$	9.1

The balance of receivables from contracts with customers listed in the table above represents the current trade receivables (including buy/sell arrangements), net of allowance for doubtful accounts. The allowance for receivables represents our best estimate of the probable losses associated with potential customer defaults. We determine the allowance based on historical experience, current collection trends, and external business factors such as economic factors, including regional bankruptcy rates, and political factors.

Performance obligations

Occasionally, we may enter into multi-year take or pay supply agreements with customers. The aggregate amount of revenue expected to be recognized related to these contracts’ performance obligations that are unsatisfied or partially unsatisfied is ~~approximately $42~~approximately $557 million ~~for~~in the ~~remainder of 2021.~~next three years. These approximate revenues do not include amounts of variable consideration attributable to contract renewals or contract contingencies. Based on our past experience with the customers under these arrangements, we expect to continue recognizing revenue in accordance with the contracts as we transfer control of the product to the ~~customer (refer to the sales of goods section for our determination of transfer of control).~~customer. However, in the case a shortfall of volume purchases occurs, we will recognize the amount payable by the customer over the remaining performance obligations in the contract.

Note 5: Inventories, Net

Inventories consisted of the following:


(in Millions)	(in Millions)	March 31, 2021		December 31, 2020		(in Millions)	March 31, 2022		December 31, 2021
Finished goods	Finished goods	$	35.3	$	36.1	Finished goods	$	39.1	$	52.2
Semi-finished goods	Semi-finished goods	46.9		46.2		Semi-finished goods	58.8		43.6
Raw materials, supplies and other		14.5		23.3
Raw materials, supplies, and other						Raw materials, supplies, and other	52.6		38.8
Inventory, net	Inventory, net	$	96.7	$	105.6	Inventory, net	$	150.5	$	134.6

~~Table of Contents~~

~~LIVENT CORPORATION~~

~~Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)~~

Note 6: Investments

In 2020, Livent entered into an agreement with The Pallinghurst Group ("Pallinghurst") relating to Québec Lithium Partners ("QLP"), a joint venture owned equally by ~~The~~ Pallinghurst ~~Group~~ and Livent, and the conduct of certain business operations and oversight, previously conducted solely by Nemaska Lithium Inc. for the development of a fully integrated lithium chemical asset located in Québec, Canada that is not yet in commercial production. QLP owns a 50% equity interest in the Nemaska Project. The Company accounts for the investment in QLP as an equity method investment on a one-quarter lag basis and it is included in Investments in our condensed consolidated balance sheets. For the three months ended March 31, ~~2021,~~2022, we recorded a ~~$1.3~~$2.2 million loss related to our 50% equity interest in QLP to Equity in net loss of unconsolidated ~~affiliates~~affiliate in our condensed consolidated statement of operations. The carrying amount of our 50% equity interest in QLP was ~~$19.9~~$29.6 million and ~~$21.2 million as of March 31, 2021 and December 31, 2020, respectively. See Note 13 for details.~~

1312

Table of Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)

$23.8 million as of March 31, 2022 and December 31, 2021, respectively.

On May 2, 2022, Livent entered into a Transaction Agreement and Plan of Merger (the “Agreement”) with Pallinghurst to provide Livent with a direct 50% ownership interest in Nemaska Lithium Inc. The Company will issue 17,500,000 shares of its common stock to Pallinghurst to acquire its 50% share of QLP. Following the close of the transaction, QLP will become a wholly owned subsidiary of Livent, and Livent will in turn own 50% of Nemaska Lithium, Inc. through QLP. Investissement Québec will remain the owner of the other 50% interest in Nemaska. The closing of the transaction is subject to certain customary mutual conditions. Pallinghurst and its investors agreed, subject to certain exceptions, to a lock-up with respect to the Livent common shares received pursuant to the Agreement that expires on August 1, 2023. Either Pallinghurst or Livent may terminate the Agreement if certain closing conditions in the Agreement are not satisfied, and both may terminate upon mutual written consent.

Note 7: Restructuring and Other Charges

The following table shows other charges included in "Restructuring and other charges" in the condensed consolidated statements of operations:


		Three Months Ended March 31,					Three Months Ended March 31,
(in Millions)	(in Millions)		2021		2020			(in Millions)	2022		2021
Restructuring charges
Restructuring charges:								Restructuring charges:
Severance-related and exit costs (1)	Severance-related and exit costs (1)		$	0	$	4.4		Severance-related and exit costs (1)	$	0.5	$	—
Other charges
Other charges:								Other charges:

Environmental remediation (2)	Environmental remediation (2)		0.1		0.1			Environmental remediation (2)	0.1		0.1
Other (3)	Other (3)		0.2		0.3			Other (3)	0.4		0.2
Total Restructuring and other charges	Total Restructuring and other charges		$	0.3	$	4.8		Total Restructuring and other charges	$	1.0	$	0.3

___________________

1.Three months ended March 31, ~~2020~~2022 includes severance costs for management changes at certain ~~operating and~~ administrative ~~facilities and exit costs of~~ ~~$1.0 million~~ ~~for the closing of leased office space.~~facilities.

2.There is 1 environmental remediation site in Bessemer City, North Carolina.

3.Three months ended March 31, 2022 and 2021 consists primarily of ~~transaction related legal fees. See Note 13 for more details. Three months ended March 31, 2020 consists primarily of~~transaction-related legal fees ~~related to IPO securities litigation.~~

~~Table of Contents~~and miscellaneous nonrecurring transactions.

~~LIVENT CORPORATION~~

~~Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)~~

Note 8: Income Taxes

We determine our interim tax provision using an estimated annual effective tax rate methodology (“EAETR”) in accordance with U.S. GAAP. The EAETR is applied to the year-to-date ordinary income, exclusive of discrete items. The tax effects of discrete items are then included to arrive at the total reported interim tax provision.

The determination of the EAETR is based upon a number of estimates, including the estimated annual pretax ordinary income in each tax jurisdiction in which we operate. As our projections of ordinary income change throughout the year, the EAETR will change period-to-period. The tax effects of discrete items are recognized in the tax provision in the period they occur in accordance with U.S. GAAP. Depending on various factors, such as the item’s significance in relation to total income and the rate of tax applicable in the jurisdiction to which it relates, discrete items in any quarter can materially impact the reported effective tax rate. As a global enterprise, our tax expense can be impacted by changes in tax rates or laws, the finalization of tax audits and reviews, as well as other factors. As a result, there can be significant volatility in interim tax provisions.

Provision for income taxes for the three months ended March 31, 2022 was $4.7 million resulting in an effective tax rate of 8.1%. Provision for income taxes for the three months ended March 31, 2021 was $0.9 million resulting in an effective tax rate of 900%. ~~Provision for income taxes~~The effective tax rate for the ~~three months~~period ended March 31, ~~2020~~2022 was ~~a benefit~~primarily impacted by fluctuations in foreign currency impacts in Argentina of ~~$0.3 million resulting in an effective tax rate of 13.6%.~~($4.3) million.

~~Note 9: Debt~~

~~Long-term debt~~

~~Long-term debt consists of the following:~~

Interest Rate
Percentage
Maturity
Date March 31, 2021 December 31, 2020
(in Millions) LIBOR borrowings Base rate borrowings
Revolving Credit Facility (1)
2.4% 4.5% 2023 $ 59.6 $ 35.6
4.125% Convertible Senior Notes due 2025 4.125% 2025 245.8 245.8
Transaction costs - 2025 Notes
(6.5) (6.8)
Total long-term debt (2)
$ 298.9 $ 274.6

1.As of March 31, 2021 and December 31, 2020, there were $14.4 million in letters of credit outstanding under our Revolving Credit Facility and $251.0 million and $275.0 million available funds as of March 31, 2021 and December 31, 2020, respectively. Fund availability is subject to the Company meeting its debt covenants.

2.~~As of March 31, 2021 and December 31, 2020, the Company had 0 debt maturing within one year.~~

On January 1, 2021, the Company elected to early adopt ASU 2020-06 under the full retrospective method, that is, the accounting change was recognized as an adjustment to the balance of retained earnings, additional paid-in capital, long-term debt and deferred income taxes in our consolidated balance sheet as of December 31, 2020, the year in which the 2025 Notes were issued.The ASU reduces the number of accounting models for convertible debt instruments by eliminating the cash conversion model. Our 2025 Notes are now reported as a single liability instrument net of transaction costs with an interest rate closer to the coupon interest rate.

~~The comparative financial statements of prior years have been adjusted to apply the adopted guidance retrospectively:~~

Table of Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)

Statement of operations
(in Millions)
Three months ended March 31, 2021 As computed under ASC 470-20 As reported under ASU 2020-06 Effect of change
Interest expense $ 2.0 $ 0.3 $ (1.7)
(Loss)/income from operations before income taxes (1.6) 0.1 1.7
Income tax expense 0.5 0.9 0.4
Net loss $ (2.1) $ (0.8) $ 1.3
Net loss per weighted average share - basic and diluted $ (0.01) $ (0.01) $ 0
Year ended December 31, 2020 As originally reported As adjusted Effect of change
Interest expense $ 3.7 $ 0.3 $ (3.4)
Loss from operations before income taxes (25.4) (22.0) 3.4
Income tax benefit (6.5) (5.7) 0.8
Net loss $ (18.9) $ (16.3) $ 2.6
Net loss per weighted average share - basic and diluted $ (0.13) $ (0.11) $ 0.02
Balance Sheet
(in Millions)
March 31, 2021 As computed under ASC 470-20 As reported under ASU 2020-06 Effect of change
Deferred income taxes $ 14.0 $ 6.1 $ (7.9)
Long-term debt 262.7 298.9 36.2
Total liabilities $ 276.7 $ 305.0 $ 28.3
Common stock, $0.001 per share par value 0.1 0.1 0
Capital in excess of par value of common stock 553.7 521.5 (32.2)
Retained earnings 55.6 59.5 3.9
Accumulated other comprehensive loss (44.7) (44.7) 0
Treasury stock (0.8) (0.8) 0
Total equity 563.9 535.6 (28.3)
Total liabilities and equity $ 840.6 $ 840.6 $ 0
December 31, 2020 As originally reported As adjusted Effect of change
Deferred income taxes $ 13.9 $ 5.6 $ (8.3)
Long-term debt 236.7 274.6 37.9
Total liabilities $ 250.6 $ 280.2 $ 29.6
Common stock 0.1 0.1 0
Capital in excess of par value of common stock 553.1 520.9 (32.2)
Retained earnings 57.7 60.3 2.6
Accumulated other comprehensive loss (44.4) (44.4) 0
Treasury stock, common, at cost (0.7) (0.7) 0
Total equity 565.8 536.2 (29.6)
Total liabilities and equity $ 816.4 $ 816.4 $ 0
Note 9: Debt

Long-term debt

Long-term debt consists of the following:


	Interest Rate Percentage			Maturity Date	March 31, 2022		December 31, 2021
(in Millions)	LIBOR borrowings	Base rate borrowings
Revolving Credit Facility (1)	2.70%	4.8%		2023	$	—	$	—
4.125% Convertible Senior Notes due 2025			4.125%	2025	245.8		245.8

Transaction costs - 2025 Notes					(5.0)		(5.4)
Total long-term debt (2)					$	240.8	$	240.4

~~Table~~1.As of ~~Contents~~March 31, 2022 and December 31, 2021, there were $14.5 million in letters of credit outstanding under our Revolving Credit Facility and $385.5 million available funds as of March 31, 2022 and December 31, 2021. Fund availability is subject to the Company meeting its debt covenants.

~~LIVENT CORPORATION~~

~~Notes to~~As of March 31, 2022 and December 31, 2021, the ~~Condensed Consolidated Financial Statements (unaudited) — (Continued)~~

Statement of cash flows
(in Millions)
Three months ended March 31, 2021 As computed under ASC 470-20 As reported under ASU 2020-06 Effect of change
Net loss $ (2.1) $ (0.8) $ 1.3
Adjustments to reconcile net loss to cash provided by operating activities:
Deferred income taxes 0.9 1.3 0.4
Deferred financing fee amortization 2.0 0.3 (1.7)
Net cash provided by operating activities 0.8 0.8 0
Net increase in cash and cash equivalents 9.9 9.9 0
Cash and cash equivalents, beginning of period 11.6 11.6 0
Cash and cash equivalents, end of period $ 21.5 $ 21.5 $ 0
Company had no debt maturing within one year.

2025 Notes

In the second quarter of ~~2021,~~2022, the holders of the 2025 Notes were notified that the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, March 31, ~~2021~~2022 was greater than or equal to 130% of the conversion price on each trading day, and as a result, the holders have the option to convert all or any portion of their 2025 Notes through June 30, ~~2021.~~2022. The 2025 Notes are classified as long-term debt.

The Company ~~recorded $0.4 million of~~recognized noncash interest ~~expense~~ related to the amortization of transaction costs ~~for the three months ended March 31, 2021, $0.1~~of $0.4 million, all of which was capitalized, for the three months ended March 31, ~~2021.~~2022. The Company recorded ~~$2.6~~$2.5 million of accrued interest expense related to the principal amount for the three months ended March 31, ~~2021.~~2022.

Revolving Credit Facility

The carrying value of our deferred financing costs was ~~$2.1~~$1.3 million as of March 31, ~~2021.~~2022.

Covenants

The Credit Agreement contains certain affirmative and negative covenants that are binding on ~~the Borrowers~~us and our subsidiary, Livent USA Corp., as borrowers (the "Borrowers") and their subsidiaries, including, among others, restrictions (subject to exceptions and qualifications) on the ability of the Borrowers and their subsidiaries to create liens, to undertake fundamental changes, to incur debt, to sell or dispose of assets, to make investments, to make restricted payments such as dividends, distributions or equity repurchases, to change the nature of their businesses, to enter into transactions with affiliates and to enter into certain burdensome agreements. Furthermore, the Borrowers are subject to financial covenants regarding leverage (measured as the ratio of debt to adjusted earnings) and interest coverage (measured as the ratio of adjusted earnings to interest expense). Our maximum allowable first lien leverage ratio is 3.5 as of March 31, ~~2021.~~2022. Our minimum allowable interest coverage ratio is 3.5. We were in compliance with all requirements of the covenants atas of March 31, ~~2021.~~

2022.

1714

Table of Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)

Note 10: Equity

As of March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, we had 2 billion shares of common stock authorized. The following is a summary of Livent's common stock issued and outstanding:

Issued Treasury Outstanding
Balance at December 31, 2020 146,461,249 (99,268) 146,361,981
Adjusted FMC RSU awards (1)
120,986 — 120,986
Livent RSU awards 71,610 — 71,610
Livent stock option awards 11,749 — 11,749
Net purchases of treasury stock - deferred compensation plan — (638) (638)
Balance at March 31, 2021 146,665,594 (99,906) 146,565,688


	Issued	Treasury	Outstanding
Balance as of December 31, 2021	161,791,602	(101,618)	161,689,984

RSU awards	49,100	—	49,100
Stock option awards	7,905	—	7,905
Purchases of treasury stock - deferred compensation plan	—	(1,624)	(1,624)



Balance as of March 31, 2022	161,848,607	(103,242)	161,745,365

~~See Note 12 to our consolidated and combined financial statements in Part II, Item 8 of our 2020 Annual Report on Form 10-K for more information on Adjusted FMC RSU awards held by FMC employees.~~

Accumulated other comprehensive loss

Summarized below is the roll forward of accumulated other comprehensive loss, net of tax.

(in Millions) Foreign currency adjustments Total
Accumulated other comprehensive loss, net of tax at December 31, 2020 $ (44.4) $ (44.4)
Other comprehensive loss before reclassifications (0.3) (0.3)
Accumulated other comprehensive loss, net of tax at March 31, 2021 $ (44.7) $ (44.7)


(in Millions)	Foreign currency adjustments		Derivative Instruments (1)		Total
Accumulated other comprehensive loss, net of tax as of December 31, 2021	$	(43.1)	$	0.2	$	(42.9)
Other comprehensive (losses)/gains before reclassifications	(1.0)		0.1		(0.9)

Accumulated other comprehensive loss, net of tax as of March 31, 2022	$	(44.1)	$	0.3	$	(43.8)


(in Millions)	(in Millions)	Foreign currency adjustments		Total		(in Millions)	Foreign currency adjustments		Derivative Instruments (1)		Total
Accumulated other comprehensive loss, net of tax at December 31, 2019		$	(48.3)	$	(48.3)
Accumulated other comprehensive loss, net of tax as of December 31, 2020						Accumulated other comprehensive loss, net of tax as of December 31, 2020	$	(44.4)	$	—	$	(44.4)
Other comprehensive loss before reclassifications	Other comprehensive loss before reclassifications	(1.8)		(1.8)		Other comprehensive loss before reclassifications	(0.3)		—		(0.3)

Accumulated other comprehensive loss, net of tax at March 31, 2020		$	(50.1)	$	(50.1)
Accumulated other comprehensive loss, net of tax as of March 31, 2021						Accumulated other comprehensive loss, net of tax as of March 31, 2021	$	(44.7)	$	—	$	(44.7)

1.See Note 12 for more information.

Reclassifications of accumulated other comprehensive loss

~~As of~~Amounts reclassified from accumulated other comprehensive loss for the three months ended March 31, ~~2021 and December 31, 2020, we~~2022 were less than $0.1 million. We did not have any open derivative ~~cash flow hedge contacts.~~positions for the three months ended March 31, 2021.

Dividends

For the three months ended March 31, ~~2021~~2022 and ~~2020,~~2021, we paid 0no dividends. We do not expect to pay any dividends in the foreseeable future.

~~Table of Contents~~

~~LIVENT CORPORATION~~

~~Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)~~

Note 11: ~~Loss~~Earnings/(Loss) Per Share

~~Loss~~Earnings/(Loss) per common share is computed by dividing net ~~loss~~income/(loss) by the weighted average number of common shares outstanding during the period on a basic and diluted basis.

Our potentially dilutive securities include potential common shares related to our stock options, ~~and~~ restricted stock units, ~~("RSU") granted in connection with the Livent Plan~~performance restricted stock units and ~~FMC Plan.~~2025 Notes. See Note 12 to our consolidated ~~and combined~~ financial statements in Part II, Item 8 of our ~~2020~~2021 Annual Report on Form 10-K for more information. Diluted ~~loss~~earnings/(loss) per share (“Diluted EPS”) considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect. Diluted EPS excludes the impact of potential common shares related to our stock options in periods in which the option exercise price is greater than the average market price of our common stock for the period. We use the if-converted method when calculating the potential dilutive effect, if any, of our 2025 Notes.

~~Loss~~

Table of Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)

Earnings/(Loss) applicable to common stock and common stock shares used in the calculation of basic and diluted ~~loss~~earnings/(loss) per share are as follows:

(in Millions, Except Share and Per Share Data) Three Months Ended March 31,
2021 2020
Numerator:
Net loss $ (0.8) $ (1.9)
Denominator:
Weighted average common shares outstanding - basic and diluted (1)
146.5 146.1
Basic and diluted loss per common share:
Net loss per weighted average share - basic and diluted $ (0.01) $ (0.01)

~~___________________~~


(in Millions, Except Share and Per Share Data)	Three Months Ended March 31,
	2022		2021
Numerator:
Net income/(loss)	$	53.2	$	(0.8)

Net income/(loss) after assumed conversion of 2025 Notes (1)	$	53.2	$	(0.8)

Denominator:
Weighted average common shares outstanding - basic	161.7		146.5
Dilutive share equivalents from share-based plans	1.6		—
Dilutive share equivalents from 2025 Notes	28.1		—
Weighted average common shares outstanding - diluted	191.4		146.5

Basic earnings/(loss) per common share:


Net income/(loss) per weighted average share - basic	$	0.33	$	(0.01)
Diluted earnings/(loss) per common share:


Net income/(loss) per weighted average share - diluted	$	0.28	$	(0.01)

1.For the three months ended March 31, ~~2021, weighted average dilutive share equivalents~~2022, all of ~~43.7 million and 1.4 million associated with~~the interest for the 2025 Notes ~~and~~was capitalized.

The following table presents weighted average share equivalents associated with share-based plans ~~respectively,~~and the 2025 Notes that were excluded from the diluted shares outstanding calculation because the result would have been antidilutive. ~~The~~See Note 11 to our consolidated financial statements in Part II, Item 8 of our 2021 Annual Report on Form 10-K for more information on the 2025 Notes are further discussed in Note 9. For the three months ended March 31, 2020, weighted average dilutive share equivalents of 0.7 million associated with share-based plans were excluded from the diluted shares outstanding calculation because the result would have been antidilutive.Notes.


(in Millions)	Three Months Ended March 31,
	2022	2021
Share equivalents from share-based plans	—	1.4
Share equivalents from 2025 Notes	—	28.1
Total antidilutive weighted average share equivalents	—	29.5

Anti-dilutive stock options

For the three months ended March 31, ~~2021 and 2020,~~2022, none of the outstanding options to purchase shares of our common stock were anti-dilutive. For the three months ended March 31, 2021, options to purchase 547,432 ~~and 1,558,912~~ shares of our common stock at an average exercise price of $20.35 ~~and $13.23~~ per share ~~respectively,~~ were anti-dilutive and not included in the computation of diluted loss per share because the exercise price of the options was greater than the average market price of the common stock for the three months ended March 31, ~~2021 and 2020.~~

2021.

~~Table of Contents~~

~~LIVENT CORPORATION~~

~~Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)~~

Note 12: Financial Instruments, Risk Management and Fair Value Measurements

Our financial instruments include cash and cash equivalents, trade receivables, other current assets, investments held in trust fund, ~~accounts payable,~~trade payables, derivatives and amounts included in ~~investments and~~ accruals meeting the definition of financial instruments. Investments in the Livent NQSP deferred compensation plan trust fund are considered Level 1 investments based on readily available quoted prices in active markets for identical assets. The carrying value of cash and cash equivalents, trade receivables, other current assets, and accounts payable approximates their fair value and are considered Level 1 investments. Our other financial instruments include the following:

Table of Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)


Financial Instrument						Valuation Method

Foreign exchange forward contracts						Estimated amounts that would be received or paid to terminate the contracts at the reporting date based on current market prices for applicable currencies.

The estimated fair value of our foreign exchange forward contracts have been determined using standard pricing models which take into account the present value of expected future cash flows discounted to the balance sheet date. These standard pricing models utilize inputs derived from, or corroborated by, observable market data such as interest rate yield curves and currency and commodity spot and forward rates. In addition, we test a subset of our valuations against valuations received from the transaction's counterparty to validate the accuracy of our standard pricing models. Accordingly, the estimates presented may not be indicative of the amounts that we would realize in a market exchange at settlement date and do not represent potential gains or losses on these agreements.

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The inputs used to measure fair value are classified into the following hierarchy:

Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 - Unadjusted quoted prices in active markets for similar assets or liabilities, or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability.

Level 3 - Unobservable inputs for the asset or liability.

The estimated fair value and the carrying amount of debt was ~~$292.8~~$692.7 million and ~~$298.9~~$240.8 million, respectively, as of March 31, ~~2021.~~2022. Our 2025 Notes are classified as Level 2 in the fair value hierarchy. ~~The estimated fair value and carrying amount of debt was $267.6 million and $236.7 million as of December 31, 2020.~~

Use of Derivative Financial Instruments to Manage Risk

We mitigate certain financial exposures connected to currency risk through a program of risk management that includes the use of derivative financial instruments. We enter into foreign exchange forward contracts to reduce the effects of fluctuating foreign currency exchange rates.

We formally document all relationships between hedging instruments and hedged items, as well as the risk management objective and strategy for undertaking various hedge transactions. This process includes relating derivatives that are designated as fair value or cash flow hedges to specific assets and liabilities on the balance sheet or to specific firm commitments or forecasted transactions. We also assess both at the inception of the hedge and on an ongoing basis, whether each derivative is highly effective in offsetting changes in fair values or cash flows of the hedged item. If we determine that a derivative is not highly effective as a hedge, or if a derivative ceases to be a highly effective hedge, we discontinue hedge accounting with respect to that derivative prospectively.

Foreign Currency Exchange Risk Management

We conduct business in many foreign countries, exposing earnings, cash flows, and our financial position to foreign currency risks. The majority of these risks arise as a result of foreign currency transactions. The primary currencies for which we have exchange rate exposure are the Euro, the British pound, the Chinese yuan, the Argentine peso, and the Japanese yen. We currently do not hedge foreign currency risks associated with the Argentine peso due to the limited availability and the high cost of suitable derivative instruments. Our policy is to minimize exposure to adverse changes in currency exchange rates. This is

~~Table of Contents~~

~~LIVENT CORPORATION~~

~~Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)~~

accomplished through a controlled program of risk management that could include the use of foreign currency debt and forward foreign exchange contracts. We also use forward foreign exchange contracts to hedge firm and highly anticipated foreign currency cash flows, with an objective of balancing currency risk to provide adequate protection from significant fluctuations in the currency markets.

Concentration of Credit Risk

Our counterparties to derivative contracts are primarily major financial institutions. We limit the dollar amount of contracts entered into with any one financial institution and monitor counterparties’ credit ratings. We also enter into master netting agreements with each financial institution, where possible, which helps mitigate the credit risk associated with our financial instruments. While we may be exposed to credit losses due to the nonperformance of counterparties, we consider this risk remote.

Table of Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)

Accounting for Derivative Instruments and Hedging Activities

Cash Flow Hedges

We recognize all derivatives on the balance sheet at fair value. On the date we enter into the derivative instrument, we generally designate the derivative as a hedge of the variability of cash flows to be received or paid related to a forecasted transaction (cash flow hedge). We record in ~~Accumulated~~accumulated other comprehensive ~~income~~loss ("AOCL") changes in the fair value of derivatives that are designated as and meet all the required criteria for, a cash flow hedge. We then reclassify these amounts into earnings as the underlying hedged item affects earnings. In contrast we immediately record in earnings changes in the fair value of derivatives that are not designated as cash flow hedges. As of March 31, ~~2021~~2022, we had open foreign currency forward contracts in AOCL in a net after-tax gain position of $0.3 million designated as cash flow hedges of underlying forecasted sales and purchases. As of March 31, 2022 we had open forward contracts with various expiration dates to buy, sell or exchange foreign currencies with a U.S. dollar equivalent of approximately $15.5 million.

A net after-tax gain of $0.3 million, representing open foreign currency exchange contracts, will be realized in earnings during the year ending December 31, ~~2020, we did not have any open~~2022 if spot rates in the future are consistent with market rates as of March 31, 2022. The actual effect on earnings will be dependent on the actual spot rates when the forecasted transactions occur. We recognize derivative ~~cash flow hedge contacts.~~gains and losses in the “Costs of sales and services” line in the condensed consolidated statements of operations.

Derivatives Not Designated As Cash Flow Hedging Instruments

We hold certain forward contracts that have not been designated as cash flow hedging instruments for accounting purposes. Contracts used to hedge the exposure to foreign currency fluctuations associated with certain monetary assets and liabilities are not designated as cash flow hedging instruments and changes in the fair value of these items are recorded in earnings.

We had open forward contracts not designated as cash flow hedging instruments for accounting purposes with various expiration dates to buy, sell or exchange foreign currencies with a U.S. dollar equivalent of approximately ~~$26.7~~$53.7 million atas of March 31, ~~2021.~~2022.

Fair Value of Derivative ~~Instruments~~Instruments.

The ~~Company had no open~~following tables provide the gross fair value and net balance sheet presentation of our derivative ~~cash flow hedge contracts~~instruments.


	March 31, 2022
	Gross Amount of Derivatives
(in Millions)	Designated as Cash Flow Hedges
Derivatives
Foreign exchange contracts	$	0.4
Total derivative assets	0.4
Net derivative assets	$	0.4


	December 31, 2021
	Gross Amount of Derivatives
(in Millions)	Designated as Cash Flow Hedges
Derivatives
Foreign exchange contracts	$	0.2
Total derivative assets	0.2
Net derivative assets	$	0.2

Table of ~~March 31, 2021 and December 31, 2020.~~Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)

Derivatives in Cash Flow Hedging Relationships

The following tables summarize the losses related to our cash flow hedges and derivatives not designated as cash flow hedging instruments. For the three months ended March 31, 2021, ~~and 2020,~~ we did not have any open derivative cash flow hedge ~~contacts.~~contracts.


(in Millions)	Total Foreign Exchange Contracts
Accumulated other comprehensive loss, net of tax as of December 31, 2021	$	0.2
Unrealized hedging gains, net of tax	0.1

Total derivatives instruments impact on comprehensive income, net of tax	0.1
Accumulated other comprehensive gain, net of tax as of March 31, 2022	$	0.3

Derivatives Not Designated as Cash Flow Hedging Instruments


		Location of Loss Recognized in Income on Derivatives		Amount of Pre-tax Loss Recognized in Income on Derivatives (1)						Location of Loss Recognized in Income on Derivatives	Amount of Pre-tax Loss Recognized in Income on Derivatives (1)
			Three Months Ended March 31,							Three Months Ended March 31,
(in Millions)	(in Millions)				2021		2020		(in Millions)		2022		2021
Foreign Exchange contracts	Foreign Exchange contracts	Cost of Sales and Services (2)			$	(0.5)	$	0.9	Foreign Exchange contracts	Cost of sales (2)	$	(1.6)	$	(0.5)

Total	Total				$	(0.5)	$	0.9	Total		$	(1.6)	$	(0.5)

____________________

1.Amounts represent the gain or loss on the derivative instrument offset by the gain or loss on the hedged item.

2.A loss of $0.1 million ~~and gain of $0.1 million~~ related to intercompany loan hedges is included in Restructuring and other charges in the consolidated statement of operations for the three months ended March 31, ~~2021~~2022 and ~~2020, respectively.~~2021.

~~Table of Contents~~

~~LIVENT CORPORATION~~

~~Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)~~

Fair Value Measurements

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Market participants are defined as buyers or sellers in the principle or most advantageous market for the asset or liability that are independent of the reporting entity, knowledgeable and able and willing to transact for the asset or liability.

Fair Value Hierarchy

We have categorized our assets and liabilities that are recorded at fair value, based on the priority of the inputs to the valuation technique, into a three-level fair-value hierarchy. The fair-value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). If the inputs used to measure the assets and liabilities fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair-value measurement of the instrument.

Table of Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)

Recurring Fair Value Measurements

The following tables present our fair-value hierarchy for those assets and liabilities measured at fair-value on a recurring basis in our condensed consolidated balance sheets.


(in Millions)	(in Millions)	March 31, 2021		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		(in Millions)	March 31, 2022		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets	Assets									Assets

Investments in deferred compensation plan (1)	Investments in deferred compensation plan (1)	$	2.8	$	2.8	$	0	$	0	Investments in deferred compensation plan (1)	$	3.8	$	3.8	$	—	$	—

Total Assets	Total Assets	$	2.8	$	2.8	$	0	$	0��	Total Assets	$	3.8	$	3.8	$	—	$	—

Liabilities	Liabilities									Liabilities

Deferred compensation plan obligation (2)	Deferred compensation plan obligation (2)	$	4.6	$	4.6	$	0	$	0	Deferred compensation plan obligation (2)	$	6.6	$	6.6	$	—	$	—

Total Liabilities	Total Liabilities	$	4.6	$	4.6	$	0	$	0	Total Liabilities	$	6.6	$	6.6	$	—	$	—


(in Millions)	(in Millions)	December 31, 2020		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		(in Millions)	December 31, 2021		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets	Assets									Assets

Investments in deferred compensation plan (1)	Investments in deferred compensation plan (1)	$	2.6	$	2.6	$	0	$	0	Investments in deferred compensation plan (1)	$	3.4	$	3.4	$	—	$	—

Total Assets	Total Assets	$	2.6	$	2.6	$	0	$	0	Total Assets	$	3.4	$	3.4	$	—	$	—

Liabilities	Liabilities									Liabilities

Deferred compensation plan obligation (2)	Deferred compensation plan obligation (2)	$	4.5	$	4.5	$	0	$	0	Deferred compensation plan obligation (2)	$	5.9	$	5.9	$	—	$	—

Total Liabilities	Total Liabilities	$	4.5	$	4.5	$	0	$	0	Total Liabilities	$	5.9	$	5.9	$	—	$	—

____________________

1.Balance is included in “Investments” in the condensed consolidated balance sheets. Livent NQSP investments in Livent common stock are recorded as "Treasury stock" in the condensed consolidated balance sheets and carried at historical cost. A mark-to-market loss of $0.2 million and gain of ~~$0.2~~$0.2 million ~~and~~ ~~$0.3 million~~ was recorded for the three months ended March 31, ~~2021~~2022 and March 31, ~~2020,~~2021, respectively, related to the Livent common stock. The mark-to-market losses and gains were recorded in "Selling, general and administrative expense" in the condensed consolidated statement of operations, with a corresponding offset to the deferred compensation plan obligation in the condensed consolidated balance sheets.

2.Balance is included in “Other long-term liabilities” in the condensed consolidated balance sheets.

~~Table of Contents~~

~~LIVENT CORPORATION~~

~~Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)~~

Note 13: Commitments and Contingencies

Contingencies

We are a party to various legal proceedings, including those noted in this section. Livent records reserves for estimated losses from contingencies when information available indicates that a loss is probable and the amount of the loss, or range of loss, can be reasonably estimated. As additional information becomes available, management adjusts its assessments and estimates. Legal costs are expensed as incurred.

In addition to the legal proceedings noted below, we have certain contingent liabilities arising in the ordinary course of business. Some of these contingencies are known but are so preliminary that the merits cannot be determined, or if more advanced, are not deemed material based on current knowledge; and some are unknown - for example, claims with respect to which we have no notice or claims which may arise in the future from products sold, guarantees or warranties made, or indemnities provided. Therefore, we are unable to develop a reasonable estimate of our potential exposure of loss for these contingencies, either individually or in the aggregate, at this time. There can be no assurance that the outcome of these

Table of Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)

contingencies will be favorable, and adverse results in certain of these contingencies could have a material adverse effect on the consolidated financial position, results of operations in any one reporting period, or liquidity.

~~IPO Securities Litigation~~

As previously reported, in May 2019, purported stockholders of the Company (the "plaintiffs") filed putative class action complaints against the Company and certain other parties (the "defendants") in federal and state courts arising out of the Company's October 2018 IPO.

On October 28, 2020, defendants entered into a stipulation of settlement with the state court plaintiffs in which the Company, on behalf of defendants, paid $7.4 million to resolve all claims related to the IPO. On October 29, 2020, the state court plaintiffs filed a motion seeking preliminary approval of the settlement. The court approved the settlement following a hearing on April 15, 2021 and a final order was issued on April 26, 2021. The settlement was intended to resolve all pending litigation relating to the IPO, including the claims in both the state and federal actions. The plaintiffs dismissed their appeal in the federal court on April 30, 2021 with prejudice in light of the settlement. The Company agreed to defend and indemnify FMC with regard to these cases.

~~Nemaska arrangement~~

As previously reported, in October 2016, we entered into a long-term supply agreement (the “Agreement”) with Nemaska. To enforce our right to supply under the Agreement, in July 2018, we filed for arbitration before the International Chamber of Commerce (in accordance with the Agreement’s terms).

On December 22, 2019, Nemaska, Nemaska Lithium Inc. and certain affiliates filed for creditor protection in Canada under the Companies’ Creditors Arrangement Act (the "CCAA") in the Superior Court of Québec (the “CCAA Court”).

On May 29, 2020, we filed the Application with the CCAA Court to obtain remittance of US $20 million held in escrow by a third party for the benefit of Livent (the “Escrow Funds”), composed of: (i) US $10 million corresponding to the reimbursement of a payment made by Livent under the Agreement and (ii) US $10 million corresponding to a termination penalty under the Agreement.

~~On June 22, 2020, we acknowledged the termination of the Agreement, withdrew our arbitration claims with prejudice, and requested the remittance of the Escrow Funds.~~

On August 24, 2020, Nemaska Lithium Inc. announced that it had accepted a sale proposal structured as a credit bid under the CCAA from a group made up of Orion Mine Finance, Investissement Québec and The Pallinghurst Group (The Pallinghurst Group acting through a new entity named Québec Lithium Partners; the "Nemaska Transaction"). In connection with the consummation of the Nemaska Transaction, Livent agreed to settle its claims against Nemaska Lithium Inc. and agreed to withdraw the Application before the CCAA Court in exchange for payment of an agreed upon portion of the Escrow Funds (subject to the final determination of any appeals).

On October 15, 2020, the Nemaska Transaction was approved by the CCAA Court pursuant to an approval and vesting order. The Supreme Court of Canada dismissed two appeals of this order by judgments dated April 29, 2021. The approval of the Nemaska Transaction is now final and executory.

~~Table of Contents~~

~~LIVENT CORPORATION~~

~~Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)~~

Livent has entered into an agreement with The Pallinghurst Group relating to Québec Lithium Partners (a joint venture owned equally by The Pallinghurst Group and Livent) and the conduct of certain business operations previously conducted solely by Nemaska Lithium Inc. for the development a fully integrated lithium chemical asset located in Québec, Canada that is not yet in commercial production.

Argentine Customs Authority

On July 31, 2020, we received notice from the Argentine Customs Authority that it was conducting an audit of Minera del Altiplano SA, our subsidiary in Argentina (“MdA”). The audit relates to the export of Lithium Carbonate from Argentina for the period January 10, 2015 through December 31, 2017. Although this relates to a period of time when MdA was a subsidiary of FMC, the Company agreed to bear any possible liability for this matter under the terms of the Tax Matters Agreement that it entered into with FMC in connection with the Separation. ~~At this point, a~~A range of reasonably possible liabilities, if any, cannot be currently estimated by the Company.

Leases

All of our leases are operating leases as of March 31, ~~2021~~2022 and December 31, ~~2020.~~2021. We have operating leases for corporate offices, manufacturing facilities, and land. Our leases have remaining lease terms of ~~1 year~~one to 15thirteen years. Quantitative disclosures about our leases are summarized in the table below.


		Three Months Ended March 31,						Three Months Ended March 31,
(in Millions, except for weighted-average amounts)	(in Millions, except for weighted-average amounts)		2021		2020		(in Millions, except for weighted-average amounts)		2022		2021
Lease Cost	Lease Cost						Lease Cost
Operating lease cost	Operating lease cost		$	0.2	$	0.6	Operating lease cost		$	0.4	$	0.2
Short-term lease cost	Short-term lease cost		0.3		0.2		Short-term lease cost		0.1		0.3

Total lease cost (1)	Total lease cost (1)		$	0.5	$	0.8	Total lease cost (1)		$	0.5	$	0.5
Other information	Other information						Other information
Cash paid for amounts included in the measurement of lease liabilities:	Cash paid for amounts included in the measurement of lease liabilities:						Cash paid for amounts included in the measurement of lease liabilities:
Cash paid for operating leases	Cash paid for operating leases		$	0.5	$	0.6	Cash paid for operating leases		$	0.4	$	0.5

__________________________

1.Variable lease cost ~~and sublease income~~ for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 was less than $0.1 million. Lease expense is classified as "Selling, general and administrative expenses" in our condensed consolidated statements of operations.

As of March 31, ~~2021 and December 31, 2020,~~2022, our operating leases had a weighted average remaining lease term of ~~10.4~~8.2 years and ~~11.7 years, respectively. As of March 31, 2021 and December 31, 2020, our operating leases had~~ a weighted average discount rate of ~~4.5% and 4.4%, respectively.~~

4.9%.

The table below presents a maturity analysis of our operating lease liabilities for each of the next five years and a total of the amounts for the remaining years.


(in Millions)	(in Millions)	Undiscounted cash flows		(in Millions)	Undiscounted cash flows
Remainder of 2021		$	0.8
2022		0.8
Remainder of 2022				Remainder of 2022	$	1.0
2023	2023	0.7		2023	1.2
2024	2024	0.6		2024	1.1
2025	2025	0.6		2025	1.1
2026				2026	0.2
Thereafter	Thereafter	2.9		Thereafter	2.8
Total future minimum lease payments	Total future minimum lease payments	6.4		Total future minimum lease payments	7.4
Less: Imputed interest	Less: Imputed interest	(1.4)		Less: Imputed interest	(1.3)
Total	Total	$	5.0	Total	$	6.1

~~Table of Contents~~

~~LIVENT CORPORATION~~

~~Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)~~

In the first quarter of 2021, we terminated our existing sublease with FMC for approximately twenty-five thousand square feet of office space used for our corporate headquarters in Philadelphia, Pennsylvania and removed the related ROU asset and lease liability of approximately $10.9 million from our condensed consolidated balance sheets. On April 13, 2021 we executed a new five-year sublease agreement with a different counterparty for approximately thirteen thousand square feet of office space for our corporate headquarters in Philadelphia, Pennsylvania and we will record a $2.1 million ROU asset and lease liability in the second quarter of 2021 related thereto.

2521

Table of Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)

Note 14: Supplemental Information

The following tables present details of prepaid and other current assets, other assets, accrued and other current liabilities, and other long-term liabilities as presented on the condensed consolidated balance sheets:


(in Millions)	(in Millions)	March 31, 2021		December 31, 2020		(in Millions)	March 31, 2022		December 31, 2021
Prepaid and other current assets	Prepaid and other current assets					Prepaid and other current assets
Tax related items						Tax related items	$	12.6	$	17.7
Prepaid expenses						Prepaid expenses	8.9		12.2
Argentina government receivable (1)	Argentina government receivable (1)	$	6.5	$	10.8	Argentina government receivable (1)	6.1		13.3
Tax related items		14.7		15.7
Other receivables	Other receivables	2.9		8.6		Other receivables	3.3		2.3
Prepaid expenses		7.9		8.2
Bank Acceptance Drafts (2)	Bank Acceptance Drafts (2)	0.3		0.2		Bank Acceptance Drafts (2)	1.7		—
Other current assets (3)		8.3		12.8
Derivative assets (Note 12)						Derivative assets (Note 12)	0.4		0.2
Other current assets						Other current assets	7.0		9.6
Total	Total	$	40.6	$	56.3	Total	$	40.0	$	55.3


(in Millions)	(in Millions)	March 31, 2021		December 31, 2020		(in Millions)	March 31, 2022		December 31, 2021
Other assets	Other assets					Other assets

Argentina government receivable (1)	Argentina government receivable (1)	$	55.2	$	55.8	Argentina government receivable (1)	$	65.7	$	55.8
Advance to contract manufacturers ~~(4)~~(3)	Advance to contract manufacturers ~~(4)~~(3)	16.4		16.3		Advance to contract manufacturers ~~(4)~~(3)	15.5		16.0
Long-term raw materials inventory						Long-term raw materials inventory	5.4		4.9
Tax related items						Tax related items	2.5		1.3
Capitalized software, net	Capitalized software, net	1.7		1.8		Capitalized software, net	1.4		1.5

Tax related items (5)		2.8		2.7
Other assets	Other assets	11.2		11.8		Other assets	10.4		11.4
Total	Total	$	87.3	$	88.4	Total	$	100.9	$	90.9

~~____________________~~_________________

1.We ~~have various subsidiaries that~~ conduct business in Argentina. AtAs of March 31, ~~2021~~2022 and December 31, ~~2020, $38.6~~ 2021, $38.4million and ~~$39.5~~$38.4 million, respectively, of outstanding receivables due from the Argentina government, which primarily represent export tax and export rebate receivables, was denominated in U.S. dollars. As with all outstanding receivable balances, we continually review recoverability by analyzing historical experience, current collection trends and regional business and political factors among other factors.

2.Bank Acceptance Drafts are a common Chinese finance note used to settle trade transactions. Livent accepts these notes from Chinese customers based on criteria intended to ensure collectability and limit working capital usage.

3.December 31, 2020 includes a $5.4 million receivable for insurance reimbursement related to the IPO litigation settlement which was netted with the IPO litigation settlement accrual (See Note 13 for details).

4.We record deferred charges for certain contract manufacturing agreements which we amortize over the term of the underlying contract.

5.~~Represents an offsetting non-current deferred asset~~ ~~of $2.8 million relating to specific uncertain tax positions and other tax related items.~~

(in Millions) March 31, 2021 December 31, 2020
Accrued and other current liabilities
Plant restructuring reserves $ 3.2 $ 3.2
Retirement liability - 401K 1.8 2.6
Accrued payroll 8.1 12.5
Severance related 0.2 2.5
Environmental reserves, current 0.5 0.6
Other accrued and other current liabilities (1)
6.6 15.3
Total $ 20.4 $ 36.7

2622

Table of Contents

LIVENT CORPORATION

Notes to the Condensed Consolidated Financial Statements (unaudited) — (Continued)

(in Millions) March 31, 2021 December 31, 2020
Other long-term liabilities
Accrued investment in unconsolidated affiliate $ 6.2 $ 6.2
Asset retirement obligations 0.3 0.3
Contingencies related to uncertain tax positions (2)
3.8 3.4
Deferred compensation plan obligation 4.6 4.5
Self-insurance reserves 1.5 1.5
Other long-term liabilities 0.9 1.3
Total $ 17.3 $ 17.2


(in Millions)	March 31, 2022		December 31, 2021
Accrued and other current liabilities
Accrued investment in unconsolidated affiliate	$	14.2	$	6.2
Accrued payroll	7.8		17.1
Plant restructuring reserves	3.2		3.2


Advance customer payments	0.7		—
Retirement liability - 401k	0.6		2.5

Environmental reserves, current	0.5		0.5
Severance related	0.3		—
Other accrued and other current liabilities (1)	26.9		32.3
Total	$	54.2	$	61.8


(in Millions)	March 31, 2022		December 31, 2021
Other long-term liabilities

Deferred compensation plan obligation	$	6.6	$	5.9
Contingencies related to uncertain tax positions (2)	4.0		2.3
Self-insurance reserves	1.5		1.5
Asset retirement obligations	0.3		0.3
Other long-term liabilities	1.7		1.7
Total	$	14.1	$	11.7

____________________

1.Amounts primarily include accrued capital expenditures related to our expansion projects. ~~December 31, 2020 includes a~~ ~~$7.4 million~~ ~~settlement accrual related to IPO litigation recorded in the third quarter of 2020. See Note 13 for details about IPO litigation settlement.~~

2.As of March 31, ~~2021,~~2022, we have recorded a liability for uncertain tax positions of ~~$3.4~~of $3.6 million and a $0.4 million indem in~~demnification~~nification liability ~~to FMC for assets~~ where the offsetting uncertain tax position is with ~~FMC.~~

FMC, per the tax matters agreement.

2723

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995: We and our representatives may from time to time make written or oral statements that are “forward-looking” and provide other than historical information, including statements contained in Item 2 of this Quarterly Report on Form 10-Q, in our other filings with the SEC, or in reports to our stockholders.

In some cases, we have identified forward-looking statements by such words or phrases as “will likely result,” “is confident that,” “expect,” “expects,” “should,” “could,” “may,” “will continue to,” “believe,” “believes,” “anticipates,” “predicts,” “forecasts,” “estimates,” “projects,” “potential,” “intends” or similar expressions identifying “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words and phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the ~~company~~Company based on currently available information. These forward-looking statements may include projections of our future financial performance, our anticipated growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement.

Currently, one of the most significant factors is the ~~potential adverse effect~~continuing effects of the ~~current~~ COVID-19 ~~pandemic on~~global pandemic. Restrictions intended to slow the ~~financial condition, results~~spread of ~~operations, cash flows~~COVID-19 have led to and ~~performance of the Company, which is substantially influenced by the potential adverse effect of the pandemic on Livent’s customers~~may continue to cause business and ~~suppliers, the~~supply chain disruptions, volatility in global ~~economy~~capital and financial markets (including inflation), and ~~costs~~a global slowdown of ~~implementing~~economic activity. The emergency measures imposed by governments on businesses and individuals, including quarantines, travel restrictions, social distancing, workforce retention rules and restrictions on the movement of workers, among other measures, have impacted and may further impact our workforce and operations, and those of our customers and suppliers. The severity of the disruptions caused by the COVID-19 ~~safety protocols.~~pandemic, and their impact on our results, will be determined by how long the COVID-19 pandemic continues, which is currently unknown. The ~~extent to which COVID-19 impacts us will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and~~ duration of the ~~pandemic,~~disruptions may be impacted by the actions ~~taken~~that governments, businesses and individuals may take in relation to ~~contain~~ the COVID-19 pandemic, ~~or mitigate its impact, and the direct and indirect economic effects~~more contagious variants of the ~~pandemic~~virus, vaccine resistance and ~~containment measures, among others.~~delays in vaccine distribution. Future disruptions could have an adverse impact on our operations and expansion activities, results, financial position and liquidity, or on our ability to successfully execute our business strategies and initiatives.

Additional factors include, among other things:

•a decline in the growth in demand for ~~electric vehicles with~~EVs using high ~~performance lithium compounds;~~

•~~reduced customer demand, or delays in growth of customer demand, for higher~~ performance lithium compounds;

•volatility in the price for performance lithium compounds;

•adverse global economic ~~conditions;~~and weather conditions that may result in adverse impact on supply chains and customer demand;

•~~competition;~~competition from other lithium producers;

•quarterly and annual fluctuations of our operating results;

•risks relating to Livent’s ~~production~~capacity expansion ~~efforts;~~efforts and current production;

•potential development and adoption of battery technologies that do not rely on performance lithium compounds as an ~~input;~~input, or that require a lesser amount of performance lithium compounds;

•difficulty accessing global capital and credit markets;

•the conditional conversion feature of the 2025 Notes;

•the lack of sufficient cash flow from our business to pay our debt;

•the success of Livent’s research and development efforts;

•future acquisitions that may be difficult to integrate or are otherwise unsuccessful;

•risks inherent in international operations and sales, including political, financial and operational risks specific to Argentina, China and other countries where Livent has active operations;

•the effects of war or other conflicts, including but not limited to, the ongoing war in Ukraine and the related sanctions against Russia, acts of retaliation by Russia (including cyber-attacks and curtailment of natural gas supplies), terrorism or other catastrophic events that may affect global supply chains, oil prices, inflation, and general economic conditions;

•operations or supply chain disruptions due to physical and other risks, including natural disasters, epidemics, pandemics, and other catastrophic events beyond our control;

•customer concentration and the possible loss of, or significant reduction in orders from, large customers;

•failure to satisfy customer qualification processes and customer and government quality standards;

•global inflation, fluctuations in the price of energy and certain raw materials;

•employee attraction and ~~retention;~~retention, especially in relation to our capacity expansion efforts;

•union relations;

•cybersecurity breaches;

•our ability to protect our intellectual property rights;

•ESG ~~matters;~~matters, including risk of not meeting our ESG targets, especially as they relate to emissions and greenhouse gas intensity, and other climate change related risks;

•we have not established “proven” or “probable” mineral reserves, as defined by the ~~lack~~SEC, through the completion of ~~proven reserves;~~a feasibility study for the minerals that we produce;

•legal and regulatory proceedings, including any shareholder lawsuits;

•compliance with environmental, health and safety laws;

•changes in tax laws;

•risks related to our separation from FMC Corporation;

•~~potential conflicts of interests among officers and directors who may own equity in, and/or may have otherwise served as employees of, FMC Corporation;~~

•risks related to ownership of our common stock, including price ~~fluctuations and the lack of dividends;~~fluctuations;

•provisions under Delaware law and our charter documents that may deter third parties from acquiring us; and

•the lack of cash dividends at this time.

Moreover, investors are cautioned to interpret many of these factors as being heightened as a result of the ongoing and numerous adverse impacts of COVID-19. You should carefully consider the risk factors discussed in Part I, Item 1A of our ~~2020~~2021 Annual Report on Form 10-K.

Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We are under no duty to and specifically decline to undertake any obligation to publicly revise or update any of these forward-looking statements after the date of this Quarterly Report on Form 10-Q to conform our prior statements to actual results, revised expectations or to reflect the occurrence of anticipated or unanticipated events.

APPLICATION OF CRITICAL ACCOUNTING ~~POLICIES~~ESTIMATES

Our condensed consolidated financial statements are prepared in conformity with U.S. GAAP. The preparation of our financial statements requires management to make ~~estimates~~judgements, assumptions and ~~judgments~~estimates that affect the reported amounts of assets, liabilities, revenues and ~~expenses.~~expenses and that have or could have a material impact on our financial condition and results of operations. We have described our accounting ~~policies~~estimates in Note 2 to our consolidated ~~and combined~~ financial statements included in Part II, Item 8 of our ~~2020~~2021 Annual Report on Form 10-K. The SEC has defined critical accounting estimates as those estimates made in accordance with U.S. GAAP that involve a significant level of measurement uncertainty and have had or are reasonably likely to have a material impact on the financial condition or operating performance of a company.

We have reviewed these accounting ~~policies,~~estimates, identifying those that we believe ~~to be~~contain matters that are inherently uncertain, have significant levels of subjectivity and complex judgments and are critical to the preparation and understanding of our condensed consolidated financial statements. We have reviewed these critical accounting ~~policies~~estimates with the Audit Committee of our Board of Directors. Critical accounting ~~policies~~estimates are central to our presentation of results of operations and financial condition and require management to make ~~estimates~~judgments, assumptions and ~~judgments~~estimates on certain matters. We base our estimates, assumptions and judgments on historical experience, current conditions and other reasonable factors.

The following is a list of those accounting ~~policies~~estimates that we have deemed most critical to the presentation and understanding of our results of operations and financial condition. See the ~~“Critical~~"Critical Accounting ~~Policies”~~Estimates" section included within "Management's Discussion and Analysis of Financial Condition and Results of Operations" within Part II, Item 7 of our ~~2020~~ 2021

Annual Report on Form 10-K for a detailed description of these ~~policies~~estimates and their potential effects on our results of operations and financial condition.

•Revenue recognition

•Trade and ~~trade~~other receivables

•Impairment and valuation of long-lived assets

•Income taxes

Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The estimates used for, but not limited to, revenue recognition and the collectability of trade receivables, impairment and valuation of long-lived assets, and income taxes could be impacted. We have assessed the impact and are not aware of any specific events or circumstances that required an update to our estimates and assumptions or materially affected the carrying value of our assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

~~RECENTLY ISSUED AND ADOPTED ACCOUNTING PRONOUNCEMENTS AND REGULATORY ITEMS~~

See Note 3 to these condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for a discussion of recently adopted accounting guidance and other new accounting guidance.

OVERVIEW

We are a pure-play, fully integrated lithium company, with a long, proven history of producing performance lithium compounds. Our primary products, namely battery-grade lithium hydroxide, lithium carbonate, butyllithium and high purity lithium metal are critical inputs used in various performance applications. Our strategy is to focus on supplying high performance lithium compounds to the ~~fast~~rapidly growing ~~Electric Vehicle (“EV”)~~EV and broader energy storage battery ~~market,~~markets, while continuing to maintain our position as a leading global producer of butyllithium and high purity lithium metal. With extensive global capabilities, ~~over 60~~approximately 80 years of continuous production experience, applications and technical expertise and deep customer relationships, we believe we are well positioned to capitalize on the accelerating trend of ~~vehicle~~ electrification.

We produce lithium compounds for use in applications that have specific and constantly changing performance requirements, including battery-grade lithium hydroxide for use in high performance lithium-ion batteries. We believe the demand for our compounds will continue to grow as the electrification of transportation accelerates, and as the use of high nickel content cathode materials increases in the next generation of battery technology products. We also supply butyllithium, which is used in the production of polymers ~~agrochemicals~~ and pharmaceutical products, as well as a range of specialty lithium compounds including high purity lithium metal, which is used in the production of lightweight materials for aerospace applications and non-rechargeable batteries. It is in these applications that we have established a differentiated position in the market through our ability to consistently produce and deliver performance lithium compounds.

First Quarter ~~2021~~2022 Highlights

The following are the more significant developments in our business during the three months ended March 31, ~~2021:~~2022:

•Revenue of $143.5 million for the three months ended March 31, 2022 increased $51.8 million, or approximately 56%, compared to $91.7 million for the three months ended March 31, 2021, ~~increased $23.2 million, or approximately 34%, compared~~primarily due to ~~$68.5~~higher pricing across all of our products partially offset by a decrease in sales volumes.

•Net income of $53.2 million for the three months ended March 31, ~~2020,~~2022 compared to net loss of $(0.8) million for the three months ended March 31, 2021 was primarily due to higher ~~sales volumes~~pricing across all of our products partially offset by ~~lower average prices.~~a decrease in sales volumes, higher logistics, raw material and other operating costs, higher Restructuring and other charges, $2.2 million Equity in net loss of unconsolidated affiliate and an increase to income tax expense. The three months ended March 31, 2021 also includes a $14.0 million gain from our sale of Argentina Sovereign U.S. dollar-denominated bonds (see Note 2 for more information).

•Adjusted EBITDA of $53.3 million for the three months ended March 31, 2022 increased $42.2 million compared to $11.1 million for the three months ended March 31, 2021, ~~increased $1.7 million, or approximately 18% compared to $9.4 million for the three months ended March 31, 2020~~ primarily due to higher pricing across all of our products partially offset by a decrease in sales volumes ~~offset by lower average prices.~~and higher logistics, raw material and other operating costs.

COVID-19 Impacts

Business and Operations

During the three months ended March 31, ~~2021,~~2022, the COVID-19 pandemic continued to negatively impact our business, operations and financial performance. Worldwide government efforts to contain the spread and mitigate the impact of COVID-19 continued. We still face operational challenges and uncertainties related to the unprecedented global COVID-19 pandemic. The disruptions and duration may be impacted by the actions that governments, businesses and individuals take in relation to the pandemic, more contagious variants of the virus, vaccine safety concerns, vaccine resistance, vaccine availability, delays in vaccine distribution and the willingness of individuals to be vaccinated.

We have manufacturing operations in the U.S., Argentina, China, the United Kingdom, and India, general operations in Singapore, and sales offices in the U.S., China, the United Kingdom, India, and Japan. All of these countries have been affected by the COVID-19 pandemic to varying degrees. Each country where we operate has adopted measures to contain ~~it,~~COVID-19, and each may adopt different and/or ~~even~~ stricter measures in the future. ~~The~~Notably, the government of ~~Argentina, where the Company’s primary lithium brine resource is located,~~China continues to enact emergency measures ~~including regional curfews and lockdowns, business and school closures, travel and immigration restrictions, and workforce retention rules. Likewise,~~ in certain geographic locations to stem the U.K. and India, the respective governments have also imposed lockdowns and similar restrictions from time to time. The most recent lockdown in the U.K. was only recently lifted, while regional lockdowns remain in place in India as the numberspread of COVID-19 ~~cases~~ and ~~deaths has risen~~may enact new ones in ~~recent weeks.~~other locations. We expect government measures and restrictions in China and globally to continue to have a negative impact on demand for certain of our products and a negative

impact on the efficient operation of our facilities, toll manufacturers, supply chains and logistics. Disruptions and delays within our supply chain and logistics operations included problems and congestion at ports, ~~due to national quarantines,~~ difficulties with scheduling cargo ships, higher shipment and freight costs, additional warehouse costs due to shipment delays, lack of driver availability and fewer transportation options, and the restriction of movements by trucks within and between countries. ~~While the~~The severity of these problems and issues has ~~generally lessened~~varied in ~~the U.S. and China~~different geographic locations over the course of the COVID-19 pandemic ~~there can be no assurance that this trend will continue given the uncertainty~~and continues to remain a challenge in all of the ~~COVID-19 pandemic.~~

countries where we operate.

Customer demand for certain types of our products ~~improved~~was flat to slightly lower during the first quarter of ~~2021.~~2022. However, customers continue to protect their interests by diversifying among multiple ~~suppliers and many remain hesitant to enter into longer term agreements. They continue to actively manage~~suppliers. In addition, customers in the fast-growing EV manufacturing industry are currently experiencing their own ~~inventory levels~~supply chain constraints and problems, including semiconductor chip shortages and multi-week shutdowns of OEMs and their suppliers in China. Supplier disruptions in Ukraine, the ~~current uncertain market environment.~~

~~In the first quarter~~semiconductor chip and wire harness shortages and shutdowns of ~~2020, because of the significant practical constraints resulting from actions being taken by authorities around the world~~OEMs and their suppliers in ~~response~~China are expected to continue and add volatility and uncertainty to the overall EV supply chain, which may adversely impact our business. This, and similar supply chain disruptions experienced by our customers could cause delays in their demand for our high performance lithium compounds, further adversely impacting our business and growth plans.

The continuing spread and effects of COVID-19, ~~pandemic, we elected to suspend all capital expansion work globally. As of the second quarter of 2021, we have resumed~~including health and safety protocols and supply and logistics disruptions in China and elsewhere, are impacting our ~~capital~~ expansion work in Argentina and the ~~United States.~~U.S. There can be no assurance that ~~this~~such impacts will not turn into long-term or continuing delays, cause us to decide to suspend our capital expansion work, ~~will not be~~or otherwise negatively ~~impacted by the continuing spread and effects of COVID-19.~~impact our capital expansion. Any significant delay in our capital expansion work in Argentina or the ~~United States~~U.S. could have ana material adverse effect on our business, financial condition and results of operations. In addition to delays, there have been increased costs due to slowdown of availability of materials and labor for construction.

We have not faced any material issues with employee morale or attrition. Likewise, we have not faced any material issues with our ability to recruit new employees or in talent management of existing employees. Broadly, we are observing tightness in the local labor markets in almost all of the geographic locations where we operate (e.g., fewer applicants and higher wages). This may impact us and our expansion efforts, our customers and suppliers in the future.

The material operational challenges that management and ~~the~~our Board of Directors are monitoring are the health and safety of our employees, ~~geographic quarantines,~~ travel restrictions, ~~social distancing, lockdowns, closure~~and testing requirements, COVID-19 mitigation measures, such as China's zero-COVID strategy, the effectiveness of ~~non-essential businesses~~remote and ~~schools,~~hybrid work ~~from home requirements, shelter in place orders, and~~arrangements, the restriction of movements within and between ~~countries.~~countries (especially in the Asia-Pacific region), and supply chain and logistics issues. Furthermore, our Board of Directors is monitoring the additional expected and unexpected impacts that COVID-19 is having on the economies in the countries where we operate, such as high inflation in the U.S., high inflation and economic instability in Argentina, and shortages of electricity in China that have led to temporary shutdowns of third party providers to the Company in the past.

Liquidity and Financial Resources

The rapid and global spread of COVID-19 has resulted in the disruption and temporary shutdown of the businesses of certain of our customers, contract manufacturers and suppliers, and limits on access to the production facilities of our contract manufacturers and suppliers. Several of our customers and contract manufacturers have experienced disruptions in their business due to the COVID-19 pandemic. Certain of our customers have canceled, postponed or delayed orders.

Our uses of cash were impacted by the effects of COVID-19 during the three months ended March 31, ~~2021.~~2022. We continue to face logistical supply disruptions, such as higher truck, freight and sea shipping ~~costs.~~costs, along with the need to use air freight from time to time. We expect this to continue. We also continue to use cash to purchase additional COVID-19 testing, personal protective equipment for our employees, such as masks and gloves, and for increased cleaning and disinfectant costs, ~~wipes and hand sanitizer,~~ additional medical personnel at our facilities, and increased personnel transportation costs due to social distancing guidelines.

Corporate Efforts

We ~~have responded~~continue to ~~the COVID-19 pandemic in~~maintain a ~~number of ways. Our~~ Global Pandemic Response Team ~~now includes a Vaccine subcommittee. The Vaccine subcommittee is tasked with monitoring vaccine developments~~ and ~~encouraging our employees to be vaccinated. The Company recently helped sponsor a local community vaccination effort in Bessemer City, North Carolina.~~regional COVID-19 Response Teams. Our regional COVID-19 Response Teams ~~continue to~~ keep Executive Leadership informed of local matters such as government policies and regulations. Our Enterprise Risk Management processes have worked as designed.

We continue to identify potential new suppliers and logistics providers for our operations ~~in case of further~~as supply chain ~~disruptions.~~challenges continue. This includes potential new suppliers of chemicals and packaging, and air freight ~~companies.~~companies when required. We have altered global production schedules to meet changes in customer ~~demand.~~demand, supply and logistics challenges. Future efforts will continue along these lines and be dictated by the particulars of the COVID-19 pandemic. We continue to plan for a ~~return to~~relaxation of COVID-19 protocols, more ~~normalized~~ business ~~operations once the COVID-19 pandemic subsides.~~travel and in-person customer contacts.

Health & Safety

We ~~are working diligently~~continue to protect the health and well-being of ~~its~~our employees, customers and other key ~~stakeholders. As an essential business under the rules of the governments~~stakeholders in ~~the countries where we operate, our~~accordance with changing circumstances and local conditions. Our plant personnel ~~continue to~~ remain on the job at their respective facilities. We ~~have~~ instituted ~~numerous~~ safety procedures to protect the health of these plant ~~personnel.~~personnel based upon local guidance. This ~~includes temperature checks before an employee enters any one of our facilities,~~can include pre-entry screening, ~~questions,~~ the use of masks and gloves, ~~where appropriate, and~~ social distancing ~~measures. We~~measures, and quarantine of close contacts with suspected or confirmed COVID-19 cases. Our non-plant personnel are ~~not permitting unvaccinated visitors~~returning to any of our facilities unless they adhere to quarantining and testing protocols, and all third-party contractors must undergo a vigorous screening process. All workers who can work from home have been requested to do so, and businesstheir offices where permitted by circumstances. Business travel ~~has been~~is slowly resuming when permitted, but is still substantially ~~reduced.~~lower than pre-pandemic levels. Communications relating to all of

these policies and COVID-19 preventative measures are regularly distributed to our ~~employees.~~employees, as there can be significant variation with respect to the COVID-19 pandemic situation in different geographic regions at any one time.

We base our health and safety protocols on the advice provided by the ~~White House, the~~ Centers for Disease Control and Prevention, the World Health Organization, and the local government authorities in the countries and regions where ~~it operates.~~we operate.

We ~~implemented the paid~~are providing customary local sick leave ~~policies that were required under the Families First Coronavirus Response Act. These policies were supplemented by our own paid sick~~benefits for absences due to COVID-19 and any other leave ~~policies.~~and benefits that may be required by local governmental authorities. We have not experienced any material employee absences as a result of COVID-19.However, ifsocial distancing measures and other health and safety protocols have led to reduced workforce numbers in certain locations, such as with our expansion project in Argentina. If a significant number of our employees at any one location were to require leave as a result of COVID-19, this could pose a risk to the continued operation of the particular facility and could potentially disrupt our broader operations.

Government Programs

We continue to evaluate government support and tax relief programs in the countries where we operate. This includes support grants, loans, tax deferrals, and tax credits.

Overall, the impact of the COVID-19 pandemic is fluid and continues to evolve, and therefore, we cannot predict the extent to which our business, results of operations, financial condition or liquidity will ultimately be impacted.

2022 Business Outlook

~~We expect higher~~To begin the year, Livent expected flat volumes and ~~slightly lower~~significantly higher average pricing across ~~our~~its lithium products in ~~the remainder of 2021~~2022, resulting in higher profitability versus the prior year. WeThe Company also ~~expect lower~~expected higher costs versus the prior year, primarily related to logistics, raw materials and general inflationary pressures.

Since this time, Livent has significantly increased its outlook for 2022 financial performance. With no expected change in volumes, this is driven ~~in part~~ by even higher ~~operating rates and the reduced impact of third-party purchased~~average pricing across all lithium ~~carbonate usage.~~products.

3228

RESULTS OF OPERATIONS


		Three Months Ended March 31,							Three Months Ended March 31,
				2021		2020					2022		2021
(in Millions)	(in Millions)		(unaudited)							(unaudited)
Revenue	Revenue			$	91.7	$	68.5	Revenue			$	143.5	$	91.7
Cost of sales	Cost of sales			78.4		53.9		Cost of sales			83.6		78.4
Gross margin	Gross margin			13.3		14.6		Gross margin			59.9		13.3
Selling, general and administrative expenses	Selling, general and administrative expenses			10.7		10.8		Selling, general and administrative expenses			11.8		10.7
Research and development expenses	Research and development expenses			0.7		1.0		Research and development expenses			0.9		0.7
Restructuring and other charges	Restructuring and other charges			0.3		4.8		Restructuring and other charges			1.0		0.3
Separation-related costs				(0.1)		0.1
Separation-related costs/(income)								Separation-related costs/(income)			0.1		(0.1)
Total costs and expenses	Total costs and expenses			90.0		70.6		Total costs and expenses			97.4		90.0
Income/(loss) from operations before equity in net loss of unconsolidated affiliates, interest expense, net and income taxes				1.7		(2.1)
Loss on debt extinguishment				—		—
Equity in net loss of unconsolidated affiliates				1.3		0.1
Income from operations before equity in net loss of unconsolidated affiliate, interest expense, net and other gain								Income from operations before equity in net loss of unconsolidated affiliate, interest expense, net and other gain			46.1		1.7
Equity in net loss of unconsolidated affiliate								Equity in net loss of unconsolidated affiliate			2.2		1.3
Interest expense, net	Interest expense, net			0.3		—		Interest expense, net			—		0.3
Income/(loss) from operations before income taxes				0.1		(2.2)
Income tax expense/(benefit)				0.9		(0.3)
Other gain								Other gain			(14.0)		—
Income from operations before income taxes								Income from operations before income taxes			57.9		0.1
Income tax expense								Income tax expense			4.7		0.9

Net loss				$	(0.8)	$	(1.9)
Net income/(loss)								Net income/(loss)			$	53.2	$	(0.8)

In addition to net ~~income,~~income/(loss), as determined in accordance with U.S. GAAP, we evaluate operating performance using certain ~~non-GAAP~~Non-GAAP measures such as EBITDA, which we define as net income plus interest expense, net, income tax ~~expense/(benefit),~~expense, and depreciation and ~~amortization,~~amortization; and Adjusted EBITDA, which we define as EBITDA adjusted for Argentina remeasurement losses, Argentina interest income, restructuring and other charges/(income), separation-related costs/(income), COVID-19 related costs, gain from sale of Argentina Sovereign U.S. dollar-denominated bonds and ~~certain~~ other ~~losses/(gains).~~loss. Management believes the use of these ~~non-GAAP~~Non-GAAP measures allows management and investors to compare more easily the financial performance of its underlying business from period to period. The ~~non-GAAP~~Non-GAAP information provided may not be comparable to similar measures disclosed by other companies because of differing methods used by other companies in calculating EBITDA and Adjusted EBITDA. These measures should not be considered as a substitute for net ~~income~~income/(loss) or other measures of performance or liquidity reported in accordance with U.S. GAAP. The following table reconciles EBITDA and Adjusted EBITDA from net ~~income.~~income/(loss).


		Three Months Ended March 31,						Three Months Ended March 31,

(in Millions)	(in Millions)		2021		2020		(in Millions)		2022		2021
Net loss (GAAP)			$	(0.8)	$	(1.9)
Net income/(loss)							Net income/(loss)		$	53.2	$	(0.8)
Add back:	Add back:						Add back:
Interest expense, net	Interest expense, net		0.3		—		Interest expense, net		—		0.3
Income tax expense/(benefit)			0.9		(0.3)
Income tax expense							Income tax expense		4.7		0.9
Depreciation and amortization	Depreciation and amortization		6.2		5.6		Depreciation and amortization		6.4		6.2
EBITDA (Non-GAAP)	EBITDA (Non-GAAP)		6.6		3.4		EBITDA (Non-GAAP)		64.3		6.6
Add back:	Add back:						Add back:
Certain Argentina remeasurement losses (a)			2.3		1.2
Argentina remeasurement losses (a)							Argentina remeasurement losses (a)		1.0		2.3
Restructuring and other charges (b)	Restructuring and other charges (b)		0.3		4.8		Restructuring and other charges (b)		1.0		0.3
Separation-related costs (c)			(0.1)		0.1
Separation-related costs/(income) (c)							Separation-related costs/(income) (c)		0.1		(0.1)
COVID-19 related costs (d)	COVID-19 related costs (d)		0.9		—		COVID-19 related costs (d)		0.8		0.9

Other gain/(loss) (e)			1.1		(0.1)
Other loss (e)							Other loss (e)		1.6		1.1
Subtract:							Subtract:
Blue Chip Swap gain (f)							Blue Chip Swap gain (f)		(14.0)		—
Argentina interest income (g)							Argentina interest income (g)		(1.5)		—
Adjusted EBITDA (Non-GAAP)	Adjusted EBITDA (Non-GAAP)		$	11.1	$	9.4	Adjusted EBITDA (Non-GAAP)		$	53.3	$	11.1

___________________

a.Represents impact of currency fluctuations on tax assets and liabilities and on long-term monetary assets associated with our capital expansion as well as ~~significant~~foreign currency devaluations. The remeasurement ~~gains/(losses)~~losses are included within "Cost of sales" in our condensed consolidated statement of operations but are excluded from our calculation of Adjusted EBITDA because of: i.) their nature as income

tax related; ii.) their association with long-term capital projects which will not be operational until future periods; or iii.) the severity of the devaluations and their immediate impact on our operations in the country.

b.We continually perform strategic reviews and assess the return on our business. This sometimes results in management changes or in a plan to restructure the operations of our business. As part of these restructuring plans, demolition costs and write-downs of long-lived assets may occur. Three months ended March 31, ~~2020~~2022 includes $0.5 million of severance costs for management changes at certain administrative facilities and $0.4 million for miscellaneous nonrecurring costs. Three months ended March 31, 2021 consists primarily of transaction-related legal fees ~~related to IPO securities litigation.~~and miscellaneous nonrecurring costs (see Note 7 for more information).

c.Represents legal and professional ~~transaction related~~ fees and other ~~Separation-related~~separation-related activity.

d.Represents incremental costs associated with COVID-19 recorded in "Cost of sales" in the condensed consolidated statement of operations, including but not limited to, incremental quarantine related absenteeism, incremental facility cleaning costs, ~~pandemic related~~COVID-19 testing, pandemic-related supplies and personal protective equipment for employees, among other costs; offset by economic relief provided by foreign governments.

e.Three months ended March 31, 2022 and 2021 represents our 25% indirect interest in ~~nonrecurring~~ transaction costs incurred for the Nemaska Transaction, certain project-related costs and interest expense, all included in Equity in net loss of unconsolidated ~~affiliates~~affiliate in our condensed consolidated statement of ~~operations related~~operations.

f.Represents the gain from the sale in Argentina pesos of Argentina Sovereign U.S. dollar-denominated bonds due to ~~our investment in Nemaska Lithium, Inc. Three months ended March 31, 2020 represents a portion~~the significant divergence of Argentina's Blue Chip Swap market exchange rate from the official rate (see Note 2 for more information) and is excluded from Adjusted EBITDA because it is nonrecurring.

g.Represents interest income received from the Argentina government for the period beginning when the recoverability of certain of our ~~nonrefundable prepaid research~~expansion-related VAT receivables were approved by the Argentina government and ~~development costs advanced to an unconsolidated affiliate in~~ending on the ~~fourth quarter 2019 and~~date when the reimbursements were paid by the Argentina government but is excluded from our calculation of Adjusted EBITDA ~~in the same period~~ because ~~the costs represent research and development activities~~ of ~~the affiliate that had~~its association with long-term capital projects which will not ~~occurred as~~be operational until future periods.

Three Months Ended March 31, 2022 vs. 2021

Revenue

Revenue of ~~December 31, 2019. These costs were included with our calculation of Adjusted EBITDA~~$143.5 million for the three months ended March 31, ~~2020 when the costs were incurred at the unconsolidated affiliate.~~

~~Three Months Ended March 31, 2021 vs. 2020~~

~~Revenue~~

~~Revenue of~~2022 (the "2022 Quarter") increased by approximately 56%, or $51.8 million, compared to $91.7 million for the three months ended March 31, 2021 (the "2021 Quarter") ~~increased by approximately 34%, or $23.2 million, compared to $68.5 million for the three months ended March 31, 2020 (the "2020 Quarter")~~primarily due to higher ~~sales volumes, driven by an increase in customer demand,~~pricing across all of our products partially offset by ~~lower average prices.~~a decrease in sales volumes.

Gross margin

Gross margin of $59.9 million for the 2022 Quarter increased by $46.6 million, or approximately 350%, versus $13.3 million for the 2021 ~~Quarter decreased by $1.3 million, or approximately 9%, versus $14.6 million for the 2020~~ Quarter. The ~~decrease~~increase in gross margin was primarily due to ~~COVID-19 costs to implement safety protocols coupled with lower average price offsetting~~ higher pricing across all of our products partially offset by a decrease in sales ~~volumes.~~volumes and higher logistics, raw material and other operating costs.

Restructuring and other charges

Restructuring and other charges of $1.0 million for the 2022 Quarter increased by $0.7 million versus $0.3 million for the 2021 ~~Quarter decreased by $4.5 million versus $4.8 million for the 2020~~ Quarter. Restructuring and other charges for the ~~2020~~2022 Quarter ~~consisted of severance-related~~included severance costs of ~~$3.4 million, accrued exit costs of $1.0~~$0.5 million for ~~the closing of leased office space and approximately $0.3 million related to IPO litigation.~~management changes at certain administrative facilities. 2021 Quarter Restructuring and other charges consisted primarily of environmental remediation and ~~transaction related~~transaction-related legal fees (see Note 7 for details).

Equity in net loss of unconsolidated ~~affiliates~~affiliate

Equity in net loss of unconsolidated ~~affiliates~~affiliate of $2.2 million and $1.3 million for the 2022 Quarter and 2021 Quarter, ~~represents~~respectively, arises out of our 25% interest in the Nemaska ~~Lithium Inc. project which includes $1.1~~Project and the increase of $0.9 million ~~of nonrecurring transaction~~represents certain project-related costs incurred ~~for the Nemaska Transaction~~ by anour unconsolidated ~~affiliate (see Note 13 for details).~~affiliate.

Interest expense, net

All $4.0 million of our interest for the 2022 Quarter was capitalized. Interest expense of $0.3 million for the 2021 Quarter is noncash amortization of transaction costs related to the 2025 Notes which represents the excess interest over the amount of interest capitalized in accordance with U.S. GAAP for the 2021 Quarter. ~~All of our interest was capitalized in the 2020 Quarter.~~

Income tax ~~expense/(benefit)~~expense

The increase in income tax expense to ~~$0.9~~$4.7 million for the ~~2021~~2022 Quarter compared to the income tax ~~benefit~~expense of ~~$0.3~~$0.9 million for the ~~2020~~2021 Quarter,was primarily ~~due to a law enacted in India eliminating tax goodwill amortization effective April 1, 2020. Additionally, the increase in tax expense was~~ due to an increase in income from ~~operations. The increase in income tax expense~~operations, which was ~~primarily~~partially offset by ~~an increase in~~ the ~~tax benefits associated with~~ fluctuations in foreign currency impacts in Argentina of ~~$1.4~~($4.3) million and ~~$0.8 million~~($1.4) for the three months ended March 31, 2022

and 2021, ~~and 2020,~~ respectively. Additionally, the increase in income tax expense was partially offset by an increase in forecasted jurisdictional mix of earnings where the statutory rate is lower than the U.S. Federal statutory rate.

Net ~~loss~~income/(loss)

Net ~~loss~~income of ~~$0.8~~$53.2 million for the ~~2021~~2022 Quarter compared to net loss of ~~$1.9~~$(0.8) million for the ~~2020~~2021 Quarter was primarily due to higher pricing across all of our products partially offset by a decrease in sales volumes, higher logistics, raw material and ~~lower~~other operating costs, higher Restructuring and other charges, ~~offset by lower average prices, incremental COVID-19 costs to implement safety protocols and a $1.3~~$2.2 million Equity in net loss of unconsolidated ~~affiliates.~~affiliate and an increase to income tax expense. The 2022 Quarter also includes a $14.0 million gain from our sale of Argentina Sovereign U.S. dollar-denominated bonds (see Note 2 for more information).

3431

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents atas of March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, were ~~$21.5~~$68.5 million and ~~$11.6~~$113.0 million, respectively. Of the cash and cash equivalents balance atas of March 31, ~~2021, $19.1~~2022, $22.4 million were held by our foreign subsidiaries. The cash held by foreign subsidiaries for permanent reinvestment is generally used to finance the subsidiaries’ operating activities and future foreign investments. We have not provided additional income taxes for any additional outside basis differences inherent in our investments in subsidiaries because the investments are essentially permanent in duration or we have concluded that no additional tax liability will arise upon disposal. ~~We have concluded the Tax Act has not altered our assertion of identifying reinvested earnings.~~ See Note 9,11, Part II, Item 8 of our ~~2020~~2021 Annual Report on Form 10-K for more information.

Revolving Credit Facility

The Credit Agreement provides for a $400 million senior secured ~~Revolving Credit Facility,~~revolving credit facility, $50 million of which is available for the issuance of letters of credit, with an option, subject to certain conditions and limitations, to increase the aggregate amount of the revolving credit commitments to $600 ~~million.~~million (the "Revolving Credit Facility"). The issuance of letters of credit and the proceeds of revolving credit loans made pursuant to the Revolving Credit Facility are available, and will be used, for general corporate purposes, including capital expenditures and permitted acquisitions, See Note ~~10,~~11, Part II, Item 8 of our ~~2020~~2021 Annual Report on Form 10-K for more information.

We had ~~$305.4 million and $281.4~~$245.8 million debt outstanding as of March 31, ~~2021~~2022 and December 31, ~~2020, respectively.~~2021. Our March 31, 2022 and December 31, 2021 debt outstanding was comprised solely of our 2025 Notes because in June 2021 we used a portion of the net proceeds from the Offering to repay all amounts outstanding under our Revolving Credit Facility. Among other restrictions, our Revolving Credit Facility contains financial covenants applicable to Livent and its consolidated subsidiaries related to leverage (measured as the ratio of debt to adjusted earnings) and interest coverage (measured as the ratio of adjusted earnings to interest expense). Our maximum allowable first lien leverage ratio is 3.5 as of March 31, ~~2021.~~2022. Our minimum allowable interest coverage ratio is 3.5. We were in compliance with all covenants atas of March 31, ~~2021.~~2022.

Statement of Cash Flows

Cash ~~provided/(required)~~provided by operating activities was ~~$12.7~~$10.8 million and ~~$(5.4)~~$12.7 million for the ~~three months ended March 31,~~2022 Quarter and 2021 ~~and 2020,~~Quarter, respectively.

The decrease in cash provided by operating activities for the 2022 Quarter as compared to the cash provided by operating activities for the 2021 Quarter ~~as compared to the cash required by operating activities for the 2020 Quarter~~ was primarily driven by ~~higher net income~~an increase in inventories and trade receivables in the ~~2021 Quarter and a decrease in payments of accounts payables in the 2021~~2022 Quarter compared to ~~the 2020 Quarter, partially offset by increased trade receivables in~~ the 2021 Quarter.

Cash ~~required by~~used in investing activities was ~~$(27.0)~~$(55.4) million and ~~$(56.3)~~$(27.0) million for the ~~three months ended March 31,~~2022 Quarter and 2021 ~~and 2020,~~Quarter, respectively.

The ~~decrease~~increase in cash ~~required by~~used in investing activities for the ~~2021~~2022 Quarter compared to the ~~2020~~2021 Quarter is primarily due to the ~~Company's election to suspend all~~ramping up of capital spending in the second half of 2021 and the 2022 Quarter as Livent resumed its capital expansion work ~~globally~~ in ~~March 2020,~~Argentina and the U.S., resulting in ~~decreased~~a significant increase in capital expenditures for ~~production~~ capacity ~~of lithium carbonate and hydroxide.~~expansion during 2022 Quarter versus the 2021 Quarter.

Cash provided by financing activities was ~~$24.2~~$0.1 million and ~~$56.5~~$24.2 million for the ~~three months ended March 31,~~2022 Quarter and 2021 ~~and 2020,~~Quarter, respectively.

Net cash proceeds ~~for~~from financing activities decreased in the ~~2021~~2022 Quarter compared to the ~~2020~~2021 Quarter ~~and was provided primarily by net draws on our~~because the Company did not draw upon its Revolving Credit Facility ~~which were used for a decreased amount~~in the 2022 Quarter primarily due to the proceeds available from the Offering in the second quarter of ~~capital expenditures for production capacity of lithium carbonate and hydroxide.~~

2021.

Other potential liquidity needs

We plan to meet our liquidity needs through available cash, cash generated from operations, borrowings under the committed Revolving Credit Facility, and other potential working capital financing strategies that may be available to us. AtAs of March 31, ~~2021,~~2022, our remaining borrowing capacity under our Revolving Credit Facility, subject to meeting our debt covenants, is ~~$251~~$385.5 million, including letters of credit utilization. ~~The First Amendment put a cap of $325 million on our overall borrowings under the Revolving Credit Facility until March 31, 2021.~~

We expect the COVID-19 pandemic uncertainties and ~~lithium market~~ challenges to continue in ~~2021.~~2022. Our net leverage ratio ~~may increase during the next 12 months as it will continue to be~~is determined, in large part, by our ability to manage the timing and amount of our capital expenditures, which is within our ~~control;~~control. It is also determined by our ability to achieve forecasted operating results and to pursue other working capital financing strategies that may be available to us, which is less certain and outside our control. In the first quarter of 2020, because of the significant practical constraints resulting from actions being taken by authorities around the word in response to the COVID-19 pandemic, the Company elected to suspend all capital expansion work globally. As of the second quarter of 2021, ~~supported by partially reduced COVID-19 related constraints, additional commitments from customers and~~

~~improved market conditions,~~ Livent resumed its capital expansion work in Argentina and the ~~United States.~~U.S. Based on this resumption, the Company estimates ~~2021~~2022 total capital spending to be ~~$125~~$300 million to $340 million. This estimate has increased slightly as a result of accelerating work as Livent looks to progress multiple expansion opportunities.

The ~~company~~Company remains focused on maintaining its financial flexibility and will continue to manage its cash flow and capital allocation decisions to navigate through this challenging environment.

We believe that our available cash and cash from operations, together with our borrowing availability under the Revolving Credit Facility and other potential financing strategies that may be available to us, will provide adequate liquidity for the next 12 months. Access to capital and the availability of financing on acceptable terms in the future will be affected by many factors, including our credit rating, economic conditions, the COVID-19 pandemic and the overall liquidity of capital markets and cannot be guaranteed.

Commitments and Contingencies

See Note 13 to these condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

Contractual Obligations and Commercial Commitments

Information related to our contractual commitments atas of December 31, ~~2020~~2021 can be found in a table included within Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations within our ~~2020~~2021 Annual Report on Form 10-K. There have been no significant changes to our contractual commitments during the period ended March 31, ~~2021.~~2022.

Climate Change

A detailed discussion related to climate change can be found in Part II, Item 7 of our ~~2020~~2021 Annual Report on Form 10-K.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

DERIVATIVE FINANCIAL INSTRUMENTS AND MARKET RISKS

Our earnings, cash flows and financial position are exposed to market risks relating to fluctuations in commodity prices, interest rates and foreign currency exchange rates. Our policy is to minimize exposure to our cash flow over time caused by changes in interest and currency exchange rates. To accomplish this, we have implemented a controlled program of risk management consisting of appropriate derivative contracts entered into with major financial institutions.

The analysis below presents the sensitivity of the market value of our financial instruments to selected changes in market rates and prices. The range of changes chosen reflects our view of changes that are reasonably possible over a one-year period. Market value estimates are based on the present value of projected future cash flows considering the market rates and prices chosen.

As of March 31, ~~2021, we had no open derivative cash flow hedge contracts.~~2022, our net financial instrument position was a net asset of $0.4 million. In the first and second ~~quarter~~quarters of ~~2021,~~2022, we placed foreign currency hedges for ~~2021~~2022 projected exposure.

Foreign Currency Exchange Rate Risk

Our worldwide operations expose us to currency risk from sales, purchases, expenses and intercompany loans denominated in currencies other than the U.S. dollar, our functional currency. The primary currencies for which we have exchange rate exposure are the Euro, the British pound, the Chinese yuan, the Argentine peso, and the Japanese yen. Foreign currency debt and foreign exchange forward contracts are used in countries where we do business, thereby reducing our net asset exposure. Foreign exchange forward contracts are also used to hedge firm and highly anticipated foreign currency cash flows. We currently do not hedge foreign currency risks associated with the Argentine peso due to the limited availability and the high cost of suitable derivative instruments.

To analyze the effects of changing foreign currency rates, we have performed a sensitivity analysis in which we assume an instantaneous 10% change in the foreign currency exchange rates from their levels ~~at the balance sheet date~~as of March 31, 2022 with all other variables (including interest rates) held constant. As of ~~March~~December 31, 2021, we had no open derivative cash flow hedge ~~contracts.~~contracts in a $0.4 million net asset position.


			Hedged Currency vs. Functional Currency
(in Millions)	Net asset position on consolidated balance sheets		Net liability position with 10% strengthening		Net asset position with 10% weakening
Net asset/(liability) position as of March 31, 2022	$	0.4	$	(1.7)	$	1.4

Interest Rate Risk

One of the strategies that we can use to manage interest rate exposure is to enter into interest rate swap agreements. In these agreements, we agree to exchange, at specified intervals, the difference between fixed and variable interest amounts calculated on an agreed-upon notional principal amount. As of March 31, ~~2021,~~2022, we had no interest rate swap agreements.

Our debt portfolio atas of March 31, ~~2021~~2022 is composed of fixed-rate and variable-rate debt; consisting of borrowings under our 2025 Notes and Revolving Credit Facility. Changes in interest rates affect different portions of our variable-rate debt portfolio in different ways. ~~Based on the variable-rate debt in our debt portfolio at~~As of March 31, ~~2021, a one percentage point increase or decrease in interest rates would have increased or decreased, respectively, gross interest expense by $0.1 million~~2022, and for the three months ended March 31, ~~2021.~~2022, we had no outstanding balances under the Revolving Credit Facility.

3734

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The information required by this item is provided in “Derivative Financial Instruments and Market Risks,” under Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations.

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures. Based on management’s evaluation (with the participation of the ~~company’s~~Company’s Chief Executive Officer and Chief Financial Officer), the Chief Executive Officer and Chief Financial Officer have concluded that, as of March 31, ~~2021,~~2022, the ~~company’s~~Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to provide reasonable assurance that information required to be disclosed by the Company in reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b) Change in Internal Controls. There have been no changes in internal control over financial reporting that occurred during the quarter ended March 31, ~~2021,~~2022, that materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

3835

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are involved in legal proceedings from time to time in the ordinary course of our business, including with respect to workers’ compensation matters. Based on information currently available and established reserves, we have no reason to believe that the ultimate resolution of any known legal proceeding will have a material adverse effect on our financial position, liquidity or results of operations. However, there can be no assurance that the outcome of any such legal proceeding will be favorable, and adverse results in certain of these legal proceedings could have a material adverse effect on our financial position, results of operations in any one reporting period, or liquidity. Except as set forth in Note 13 to our financial statements, which is incorporated herein by reference to the extent applicable, there are no material changes from the legal proceedings previously disclosed in our ~~2020~~2021 Annual Report on Form 10-K.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors discussed in Part I, Item 1A of our ~~2020~~2021 Annual Report on Form 10-K, which is available at www.sec.gov and on our website at www.livent.com. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may adversely affect our business, financial condition or future results.

Forward-Looking Information

We wish to caution readers not to place undue reliance on any forward-looking statements contained herein, which speak only as of the date made. We specifically decline to undertake any obligation to publicly revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Repurchases of Common Shares

A summary of our repurchases of Livent's common stock for the three months ended March 31, ~~2021~~2022 is as follows:

ISSUER PURCHASES OF EQUITY SECURITIES
Period
Total Number of Shares Purchased (1)
Average Price Paid Per Share
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)
Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs (2)
January 1 through January 31, 2021 185 $ 21.48 $ — $ —
February 1 through February 28, 2021 385 $ 19.36 — —
March 1 through March 31, 2021 686 $ 18.79 — —
Total Q1 2021 1,256 $ 19.36 $ — $ —


ISSUER PURCHASES OF EQUITY SECURITIES

Period	Total Number of Shares Purchased (1)	Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)		Maximum Number of Shares That May Yet Be Purchased Under the Plans or Programs (2)
January 1 through January 31, 2022	146	$	23.11	$	—	$	—
February 1 through February 28, 2022	201	$	21.63	—		—
March 1 through March 31, 2022	1,277	$	24.98	—		—
Total Q1 2022	1,624	$	24.40	$	—	$	—

~~(1)~~

1.The trustee of the Livent NQSP reacquires shares of Livent common stock from time to time through open-market purchases relating to investments by employees in our common stock, one of the investment options available under the Livent NQSP. Such shares are held in a trust fund and recorded to Treasury stock in our condensed consolidated balance sheets.

~~(2)~~ 2.We have no publicly announced stock repurchase programs.

3936

ITEM 6. EXHIBITS


10.1†						Form of Employee P RSU Award Agreement under the Livent Corporation Incentive Compensation and Stock Plan
31.1						Certifying Statement of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2						Certifying Statement of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1						Certifying Statement of the Chief Executive Officer pursuant to Section 1350 of Title 18 of the United States Code
32.2						Certifying Statement of the Chief Financial Officer pursuant to Section 1350 of Title 18 of the United States Code
101						Interactive Data File
104						The cover page from Livent Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, ~~2021,~~2022, formatted in Inline XBRL.

† Management contract or compensatory plan or arrangement

4037

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			LIVENT CORPORATION (Registrant)

			By:			/s/ GILBERTO ANTONIAZZI
						Gilberto Antoniazzi, Vice President and Chief Financial Officer

Date: May ~~6, 2021~~5, 2022

4138


Statement of operations
(in Millions)
Three months ended March 31, 2021	As computed under ASC 470-20		As reported under ASU 2020-06		Effect of change
Interest expense	$	2.0	$	0.3	$	(1.7)

(Loss)/income from operations before income taxes	(1.6)		0.1		1.7
Income tax expense	0.5		0.9		0.4
Net loss	$	(2.1)	$	(0.8)	$	1.3
Net loss per weighted average share - basic and diluted	$	(0.01)	$	(0.01)	$	0

Year ended December 31, 2020	As originally reported		As adjusted		Effect of change
Interest expense	$	3.7	$	0.3	$	(3.4)
Loss from operations before income taxes	(25.4)		(22.0)		3.4
Income tax benefit	(6.5)		(5.7)		0.8
Net loss	$	(18.9)	$	(16.3)	$	2.6
Net loss per weighted average share - basic and diluted	$	(0.13)	$	(0.11)	$	0.02

Balance Sheet
(in Millions)
March 31, 2021	As computed under ASC 470-20		As reported under ASU 2020-06		Effect of change




Deferred income taxes	$	14.0	$	6.1	$	(7.9)
Long-term debt	262.7		298.9		36.2
Total liabilities	$	276.7	$	305.0	$	28.3
Common stock, $0.001 per share par value	0.1		0.1		0
Capital in excess of par value of common stock	553.7		521.5		(32.2)
Retained earnings	55.6		59.5		3.9
Accumulated other comprehensive loss	(44.7)		(44.7)		0
Treasury stock	(0.8)		(0.8)		0
Total equity	563.9		535.6		(28.3)
Total liabilities and equity	$	840.6	$	840.6	$	0


December 31, 2020	As originally reported		As adjusted		Effect of change





Deferred income taxes	$	13.9	$	5.6	$	(8.3)
Long-term debt	236.7		274.6		37.9
Total liabilities	$	250.6	$	280.2	$	29.6
Common stock	0.1		0.1		0
Capital in excess of par value of common stock	553.1		520.9		(32.2)
Retained earnings	57.7		60.3		2.6
Accumulated other comprehensive loss	(44.4)		(44.4)		0
Treasury stock, common, at cost	(0.7)		(0.7)		0
Total equity	565.8		536.2		(29.6)
Total liabilities and equity	$	816.4	$	816.4	$	0